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1 Summary 
 
Cardiac healing after myocardial infarction (MI) represents the cardinal prerequisite 
for proper replacement of the irreversibly injured myocardium. In contrast to innate 
immunity, the functional role of adaptive immunity in postinfarction healing has not 
been systematically addressed. The present study focused on the influence of CD4+ 
T lymphocytes on wound healing and cardiac remodeling after experimental 
myocardial infarction in mice. Both conventional and Foxp3+ regulatory CD4+ T cells 
(Treg cells) became activated in heart draining lymph nodes after MI and accumulated 
in the infarcted myocardium. T cell activation was strictly antigen-dependant as T cell 
receptor-transgenic OT-II mice in which CD4+ T cells exhibit a highly limited T cell 
receptor repertoire did not expand in heart-draining lymph nodes post-MI. Both OT-II 
and major histocompatibility complex class II-deficient mice lacking a CD4+ T cell 
compartment showed a fatal clinical postinfarction outcome characterized by 
disturbed scar tissue construction that resulted in impaired survival due to a 
prevalence of left-ventricular ruptures.  
To assess the contribution of anti-inflammatory Treg cells on wound healing after MI, 
the Treg cell compartment was depleted using DEREG mice that specifically express 
the human diphtheria toxin receptor in Foxp3-positive cells, resulting in Treg cell 
ablation after diphtheria toxin administration. In a parallel line of experiments, a 
second model of anti-CD25 antibody-mediated Treg cell immuno-depletion was used.  
Treg cell ablation prior to MI resulted in adverse postinfarction left-ventricular dilatation 
associated with cardiac deterioration. Mechanistically, Treg cell depletion resulted in 
an increased recruitment of pro-inflammatory neutrophils and Ly-6Chigh monocytes 
into the healing myocardium. Furthermore, Treg cell-ablated mice exhibited an 
adverse activation of conventional non-regulatory CD4+ and CD8+ T cells that 
showed a reinforced infiltration into the infarct zone. Increased synthesis of TNFα 
and IFNγ by conventional CD4+ and CD8+ T cells in hearts of Treg cell-depleted mice 
provoked an M1-like macrophage polarization characterized by heightened 
expression of healing-compromising induced NO synthase, in line with a reduced 
synthesis of healing-promoting transglutaminase factor XIII (FXIII), osteopontin 
(OPN) and transforming growth factor beta 1 (TGFβ1).   
Therapeutic Treg cell activation by a superagonistic anti-CD28 monoclonal antibody 
stimulated Treg cell accumulation in the infarct zone and led to an increased 
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expression of mediators inducing an M2-like macrophage polarization state, i.e. 
interleukin-10, interleukin-13 and TGFβ1. M2-like macrophage differentiation in the 
healing infarct was associated with heightened expression of scar-forming pro-
collagens as well as scar-stabilizing FXIII and OPN, resulting in improved survival 
due to a reduced incidence of left-ventricular ruptures. Therapeutic Treg cell activation 
and the induction of a beneficial M2-like macrophage polarization was further 
achieved by employing a treatment modality of high clinical potential, i.e. by 
therapeutic administration of IL-2/ anti-IL-2 monoclonal antibody complexes. The 
findings of the present study suggest that therapeutic Treg cell activation and the 
resulting improvement of healing may represent a suitable strategy to attenuate 
adverse infarct expansion, left-ventricular remodeling, or infarct ruptures in patients 
with MI.  
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2 Zusammenfassung 
 
Die kardiale  Wundheilung nach einem Herzinfarkt ist unabdingbare Voraussetzung 
um das unwideruflich beschädigte Myokard zu ersetzen. Im Gegensatz zur Rolle der 
angeborenen Immunität ist zur Bedeutung der adaptiven Immunität für die kardiale 
Wundheilung nur wenig bekannt. Im Fokus der Studie stand deshalb die Rolle von 
CD4+ T-Zellen bei der Wundheilung und kardialem Remodeling nach einem 
experimentellen Herzinfarkt im Mausmodell. Sowohl konventionelle, als auch Foxp3-
positive regulatorische CD4+ T Zellen (Treg-Zellen) wurden im Lymphknoten 
infarzierter Tiere aktiviert und akkumulierten im Infarktareal. Die Aktivierung von 
CD4+ T Zellen nach MI setzte die Erkennung von Selbstantigenen voraus, da OT-II 
Tiere, die ein stark eingeschränktes T-Zell-Rezeptor-Repertoire aufweisen, keine T-
Zell-Aktivierung zeigten. Sowohl OT-II Tiere, als auch 
Haupthistokompatibilitätskomplex Klasse II Knock-out Mäuse, die kein CD4+ T-Zell 
Kompartment aufweisen, zeigten einen fatalen klinischen Phänotyp, welcher durch 
eine gestörte Narbenbildung und damit verbunden einem verstärkten Auftreten 
linksventrikulärer Rupturen verbunden war.  
Um den Einfluss anti-inflammatorischer Treg-Zellen auf die kardiale Wundheilung 
nach Herzinfarkt zu untersuchen, wurde das Treg-Zell Kompartment vor MI Induktion 
depletiert. Hierzu wurden DEREG Mäuse verwendet, in denen Foxp3-positive Zellen 
den humanen Diphtherietoxin-Rezeptor exprimieren, sodass nach nach 
Diphtierietoxin-Applikation die Treg-Zellen spezifisch depletiert werden. In einer dazu 
parallel verlaufenden Versuchsreihe wurden die Treg-Zellen mittels anti-CD25 
monoklonaler Antikörper depletiert. Die Depletion des Treg-Zell Kompartments 2 Tage 
vor MI Induktion bewirkte ein verschlechtertes links-ventrikuläres Remodeling und 
damit einhergehend eine signifikante Verschlechterung der Herzfunktion. 
Mechanistisch führte die Treg-Zell Depletion zu einer verstärkten Rekrutierung pro-
inflammatorischer Ly-6Chigh Monozyten und neutrophilen Granulozyten ins 
Infarktareal. Die Depletion von Treg-Zellen war weiterhin mit einer adversen 
Aktivierung konventioneller CD4+ und CD8+ T-Zellen assoziiert, die eine verstärkte 
Infiltration ins infarzierte Myokard zeigten. Die erhöhte Synthese von TNFα und IFNγ 
in konventionellen T-Zellen führte zu einer M1-Makrophagen Polarisierung, welche 
durch eine verstärkte Expression der induzierbaren NO Synthase charakterisiert war. 
Weiterhin exprimierten diese M1 Makrophagen signifikant weniger der für eine 
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geordnete Heilung essentiellen Faktoren Osteopontin, Transglutaminase Faktor XIII 
und transforming growth factor beta 1 (TGFβ1).  
Im Gegensatz zu den Depletionsversuchen führte die therapeutische Aktivierung der 
Treg-Zellen durch einen superagonistischen anti-CD28 monoklonalen Antikörper zu 
einer verstärkten Rekrutierung von Treg-Zellen ins Infarktareal und bewirkte eine 
erhöhte Synthese von Interleukin (IL)-10, IL-13 sowie TGFβ1. Die damit 
einhergehende M2 Makrophagenpolarisierung im Infarktareal war mit einer 
verstärkten Narbenbildung sowie der Synthese von Osteopontin und 
Transglutaminase Faktor XIII verbunden, welche sich stabilisierend auf die 
Narbenbildung auswirken. Folgerichtig zeigten die behandelten Tiere ein 
verbessertes Überleben aufgrund einer signifikant verringerten Inzidenz 
linksventrikulärer Rupturen. Alternativ zum superagonistischen anti-CD28 
monoklonalen Antikörper wurde ein weiterer klinisch relevanter Ansatz zur 
therapeutischen Aktivierung von Treg-Zellen verfolgt. Durch die Applikation von IL-2/ 
anti-IL-2 Antikörper-Komplexen konnte ebenfalls eine M2 Makrophagenpolarisierung 
hervorgerufen werden, die mit einer verstärkten Narbenbildung einherging. Die 
Ergebnisse der vorliegenden Studie deuten darauf hin, dass eine therapeutische 
Aktivierung von Treg-Zellen bei Infarktpatienten und die dadurch hervorgerufene 
Verbesserung der Wundheilung potentiell einen geeigneten Ansatz darstellt, durch 
welchen adverses linksventrikuläres Remodeling sowie Infarktrupturen verhindert 
werden können.  
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3 Introduction 
 
Myocardial infarction (MI) is an acute, life-threatening event and represents one of 
the most frequent causes of morbidity and mortality in the industrial nations. The 
disease accounts for 30% of deaths worldwide and costs global economy estimated 
U.S. $863 billion per year1. In most instances of ischemic cardiac injury, thrombus 
formation after rupture of a vulnerable atherosclerotic plaque causes the occlusion of 
a coronary artery. The interruption of blood supply to a part of the heart muscle that 
is feeded by the obstructed vessel leads to oxygen deprivation and, subsequently, 
acute MI characterized by necrosis of cardiac-resident cells such as parenchymal 
cardiomyocytes, endothelial cells, and fibroblasts2, 3. In order to restore blood flow, 
most cases of MI are treated by reperfusion therapy, i.e. by percutaneous coronary 
intervention or pharmacological thrombus lysis4. However, MI inflicts a wound to the 
heart and the perishing cells release signals that activate the host´s immune system 
to initiate postinfarction cardiac healing involving inflammatory and anti-inflammatory 
reactions5. The quality of cardiac wound healing and therefore postinfarction clinical 
outcome is pivotally influenced by the host´s immune system that facilitates cell 
debris clearance in the infarct zone and replacement of the irreversibly injured 
myocardium by a solid scar. Immunity has originally evolved as a defence system 
comprising different organs, cell types and molecules that protect the body from 
disease. Aside of its role in pathogen elimination and healing, the system is able to 
prevent malignancies, but is also involved in the rejection of allografts6. Generally, 
the immune system is subdivided into two major branches, i.e. innate and adaptive 
immunity6.  
3.1 Innate immunity 
Mechanical barriers like epithelial cells or soluble factors such as the complement 
system constitute a first line of defence against invading pathogens. Myeloid cells 
comprising monocytes, macrophages, dendritic cells, NK cells as well as neutrophilic, 
basophilic and eosinophilic granulocytes represent the cellular components of the 
innate immune system7. Bearing germline-encoded receptors (pathogen recognition 
receptors, PRRs), the cells are capable of sensing pathogen-derived molecular 
patterns (PAMPs) that, after engagement, provoke active germ elimination by the 
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means of pathogen phagocytosis or the secretion of toxic granules8. A cardinal task 
of innate immune cells is to trigger inflammation by the release of pro-inflammatory 
mediators6. Furthermore, macrophages and dendritic cells are able to present 
antigens on major histocompatibility complexes (MHC) which constitutes a 
prerequisite for T cell activation (“priming”) in terms of an adaptive immune 
response6. Aside of pathogen elimination, innate immune cells play a dominant role 
in wound healing processes such as during scar tissue construction in the infarcted 
myocardium. Danger-associated molecular patterns (DAMPs) released from injured 
tissues are capable of engaging PRRs9. Activated innate immune cells contribute 
substantially to healing by cell debris clearance, and by the secretion of growth 
factors and cytokines involved in orchestrating the reparative response10.  
3.2 Adaptive immunity 
In addition to innate immunity, an adaptive immune system has evolved in higher 
vertebrates comprising cellular and humoral effectors7. T and B lymphocytes 
represent the cellular components arising from lymphoid progenitor cells in the bone 
marrow, and antibodies secreted from B cell-derived plasma cells mediate humoral 
immune reactions. In contrast to innate immunity, an adaptive immune response 
mounts slow, imprints an immunological memory and is highly specific due to the 
principle of clonal selection. T and B cells bear an individual antigen receptor (T cell 
receptor, TCR and B cell receptor, BCR) generated by random somatic 
recombination of receptor encoding gene segments. Cells that encounter their 
cognate antigen during an immune response become activated and expand in a 
clonal fashion ensuring an efficient and highly specific immune reaction7. 
3.2.1 Development of CD4+ and CD8+ αβ T lymphocytes 
T cells originate from hematopoietic stem cells (HSCs) residing in specialized bone 
marrow niches. HSC-derived lymphoid progenitors leave the bone marrow, populate 
the cortex of the thymus and expand by cellular division to generate a large pool of 
immature thymocytes11. In the double-negative (DN) CD4-CD8- developmental stage, 
thymocytes start rearranging TCR gene segments at the DNA level characterized by 
somatic recombination of V- and J-segments, or, V-, D- and J-segments encoding 
the TCR alpha (α) or beta (β) chain, respectively. Successful recombination of the 
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TCR beta chain results in expression and formation of a pre-TCR composed of the 
“rearranged” beta chain and a surrogate TCR alpha chain. In the subsequent double-
positive (DP) CD4+CD8+ stage, successful somatic recombination is completed by 
formation of a mature, heterodimeric αβ TCR11. Individual recombination in each T 
cell generates a highly diverse TCR repertoire comprising both non-functional or 
potentially autoreactive receptors. A two-stage selection process ensures that only 
functional T cells without specificity for self-antigens exit the thymus. Migrating from 
the cortex to the thymic medulla, thymocytes interact with macrophages, dendritic 
cells, cortical thymic epithelial cells (cTECs) and medullary thymic epithelial cells 
(mTECs) presenting self-peptides loaded on MHC molecules11. T cells bearing a low 
affinity TCR for the peptide-MHC complexes receive survival signals resulting in 
positive selection. T cells which are not capable of interacting with peptide-MHC 
complexes die by apoptosis due to a lack of TCR engagement. However, a fraction 
of cells that bear a TCR of intermediate self-reactivity develops into so-called 
naturally occurring Foxp3+ regulatory CD4+ T cells12. 
Positive selection accounts for MHC-restricted antigen recognition and therefore T 
cell lineage commitment11. Thymocytes recognizing peptide-MHC I complexes 
develop into CD8+ cytotoxic T cells, whereas positive selection in the context of MHC 
class II results in commitment to the CD4+ helper T cell lineage. The subsequent 
process of negative selection assures deletion of potentially harmful auto-reactive 
cells from the selected repertoire13. Medullary thymic epithelial cells are capable of 
presenting tissue-restricted antigens expressed in specialized peripheral tissues such 
as insulin-derived peptides from the pancreas (Fig.  1). T cells that bear a TCR 
reactive for the presented self-antigens die by apoptosis13, 14. However, as central 
tolerance is not perfect, peripheral tolerance mechanisms have evolved, e.g 
peripheral immuno-suppression by regulatory cells14. 
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Fig.  1: Development of αβ T cells. Lymphoid progenitors originating from the hematopoietic stem 
cells (HSC) seed the thymus and undergo somatic recombination of TCR gene segments at the 
double-negative (DN) stage. Successful rearrangement of V-J and V-D-J segments results in 
expression of a functional TCR. Thymocytes bearing a functional TCR recognize self-peptides in the 
context of major histocompatibility complex (MHC) class I or class II on cortical thymic epithelial cells 
(cTECs) and become positively selected towards CD8+ or CD4+ T cells. Thymocytes bearing non-
functional TCRs undergo apoptosis (“death by neglect”). During subsequent negative selection, T cells 
interact with meduallary thymic epithelial cells (mTECs) or dendritic cells (DCs). Thymocytes bearing 
highly reactive TCRs undergo apoptosis whereas TCRs of low affinity induce weak signaling 
promoting further positive selection. A small subset of CD4+ cells experience intermediate signals and 
develop into CD25+Foxp3+ regulatory T cells. Mature T cells exit the thymus and circulate freely in the 
lymphoid system. The content of the figure is based on (11, 12, 13, 14). 
 
3.2.2 Antigen-presenting cells and T cell activation 
T cell activation takes place in secondary lymphoid organs such as the lymph node7. 
The cells enter the organ via high endothelial venules or the afferent lymphatics and 
interact with professional antigen-presenting cells (APCs) that display antigens on 
their surface15, 16. Professional APCs comprise dendritic cells (DCs), monocytes, 
macrophages and B cells7. After phagocytosis or pinocytosis-mediated antigen 
internalization, APCs degrade the antigen in acidic lysosomes and present the 
antigen-derived peptides on both MHC class I (“cross-presentation”) and MHC class 
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II molecules17, 18. Intracellular antigens such as peptides derived from host proteins or 
intracellular pathogens are presented on MHC class I17, 19. The entity of all MHC 
antigens is termed H-2 antigen in mice, and human leukocyte antigen in men. An 
individual´s MHC repertoire is polygenic comprising multiple genes that are co-
dominantly expressed from both chromosomes20. MHC alleles in a population are 
highly polymorphic, i.e. diversely varying from individual to individual within a certain 
species6, 20.  
T cell priming requires TCR ligation by the cognate peptide-MHC complex and CD28 
co-stimulation by B7 molecules that are upregulated on the surface of activated 
APCs21, 22. The activation of APCs results from an engagement of pathogen 
recognition receptors such as Toll-like receptors by pathogen- or danger associated 
molecular patterns. After T cell priming, conventional non-regulatory T cells secrete 
significant amounts of interleukin-2 (IL-2) that represents a central T cell growth and 
differentiation factor23. Activated T cells upregulate their IL-2 receptor alpha chain 
(CD25) to further increase their receptor affinity for the ligand24. Eventually, 
differentiated effector T cells leave the lymph node via efferent lymphatics and home 
to inflammatory sites where they exert specific effector functions7 (Fig.  2). 
Due to their potency to express high levels of MHC and co-stimulatory B7 molecules 
on their surface, DCs represent likely the most important APCs. Generally, three DC 
subgroups can be distinguished, i.e. monocyte-derived DCs (mDCs), conventional 
DCs (cDC) and plasmacytoid DCs (pDC)25. Both cDC and pDC reside in lymphoid 
and non-lymphoid peripheral tissues and originate from a common DC precursor in 
the bone marrow26, 27. In contrast, mDCs differentiate from blood monocytes that 
significantly potentiate their immunogenic capacity in presence of lipopolysaccharide, 
or gram-negative bacteria28. Lymphoid-resident DCs reside in secondary lymphoid 
organs and capture antigens from the lymph26, whereas tissue-resident DCs migrate 
actively to the draining lymph nodes to present the sampled antigens26. However, the 
other professional APCs are also able to activate T cells. In analogy to DCs, 
lymphoid-resident macrophages are distinguished from tissue-resident macrophages 
with migratory capacity29, 30 26. Monocytes and B cells circulate freely in the blood and 
the lymphatic system. To interact with T cells, monocytes and B cells enter 
secondary lymphoid organs via high endothelial venules, or afferent lymphatic 
vessels31, 32.  
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The APC activation state dictates T cell effector cell differentiation during priming. 
Depending on the quality of PRR ligands, APCs upregulate distinct mediators that 
direct the outcome and function of CD4+ T cell differentiation (see 3.2.3). Intracellular 
bacteria and viruses, for instance, induce the secretion interleukin (IL)-12 and an 
upregulation of Notch receptor ligands, i.e. Delta-like (DLL) 1 and DLL 433, 34. IL-12 
receptor engagement and Notch ligation by DLL ligands promote the differentiation 
towards the T helper type 1 (Th1) CD4+ T cell subset33, 35. In contrast, extracellular 
parasites such as Schistosoma mansoni or Vibrio cholera induce an upregulation of 
Jagged 1 and Jagged 2 on the DC surface33, 36. Notch engagement by the Jagged 
ligands, in turn, can induce Th2 subset differentiation34, 37. More recently, the ligation 
by C-type lectin receptors by carbohydrates derived from the cell wall of fungi or 
certain bacteria has been demonstrated to initiate DC maturation associated with the 
production of Th17-polarizing cytokines38. 
In addition to their relevance for the initiation of an immune reaction, the DC 
maturation state is decisive in terms of peripheral tolerance induction. In contrast to 
Fig.  2: T cell activation in secondary lymphoid organs. Tissue-resident and lymphoid-
resident APCs continuously sample and present foreign as well as self-antigens on MHC 
molecules. Engagement of PRRs by DAMPs or PAMPs in terms of inflammation results in 
APC activation characterized by an upregulation of costimulatory and accessory molecules 
such as B7. Peptide-MHC recognition via cognate TCRs on naïve T cells in presence of 
costimulation provokes T cell activation and proliferation. Activated conventional CD4+ and 
CD8+ T cells secrete IL-2 that further promotes T cell proliferation and differentiation in an 
autocrine and paracrine fashion. Depending on the prevailing cytokine milieu and the APC 
activation state, CD4+ T cells differentiate into distinct T cell subsets such as Th1 cells. 
Differentiated cells leave the lymph nodes and home to the inflammatory site where the cells 
exert specific effector functions.  
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mature DCs, immature DCs express low levels of MHC and neither co-stimulatory 
molecules, nor inflammatory cytokines39. Antigen recognition on immature DCs in 
absence of co-stimulation results in T cell anergy and constitutes an important 
mechanism to impart tolerance on the peripheral T cell repertoire towards the 
presented antigens39, 40, 41. Furthermore, a third DC maturation state has been 
described. These semi-mature DCs are tolerogenic and express high levels of both 
MHCII and co-stimulatory molecules, but lack the secretion of inflammatory 
cytokines39. In presence of TGFβ or retinoic acid, T cell priming by semi-mature DCs 
can provoke the peripheral induction of Foxp3+ regulatory CD4+ T cells42. 
 
3.2.3 T cell subsets 
3.2.3.1 Conventional T cells 
In secondary lymphoid organs, CD4+ and CD8+ T cells become activated in response 
to TCR engagement by cognate peptide-MHC complexes in presence of CD28-
mediated co-stimulatory signals7, 43. Professional antigen-presenting cells such as 
dendritic cells present the peptides on MHC class I as well as class II molecules on 
their surface and provide the indispensable co-stimulatory signals in form of B7 
molecules that engage CD28 on the T cell surface. Naive CD8+ T cells recognize 
peptides in the context of MHC class I molecules and differentiate into CD8+ cytotoxic 
T cells that are capable of secreting perforins, granzymes and cytotoxic cytokines to 
induce apoptosis in infected or malignant target cells44. In contrast, CD4+ T cells 
recognize peptides loaded on MHC class II.  After priming, effector cell differentiation 
obeys the prevailing cytokine milieu45 (Fig.  3). Both IL-12 and IFNγ induce T helper 
type 1 (Th1) cells that mediate immune reactions against intracellular pathogens by 
releasing pro-inflammatory cytokines such as IFNγ or TNFα. IL-4 and IL-13, in 
contrast, favor Th2 subset polarization that is involved in humoral immune responses 
as Th2 cells stimulate B cell proliferation as well as B cell receptor class switching. 
Furthermore, Th2 cells mediate immune reactions against extracellular pathogens 
including helminths. However, Th2 cells play also a critical role in pathologic immune 
disorders such as allergic reactions or in settings of chronic inflammation. Pro-
inflammatory Th17 cells develop in presence of TGFβ and IL-6 and contribute to 
immune reactions against certain types of microbes such as extracellular bacteria or 
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fungi, especially at epithelial or mucosal barriers. However, Th17 are deregulated in 
some autoimmune disorders causing inflammation and tissue destruction, e.g. in 
terms of multiple sclerosis or psoriasis46. Follicular helper T cells (TFH cells) are 
created in secondary lymphoid organs in presence of IL-6 and IL-2147. TFH cells 
secrete IL-21 and upregulate CD40L to interact with CD40 on cognate follicular B 
cells that present peptide-MHC complexes to the T cells. This interaction, in turn, 
supports the formation of a germinal center and promotes follicular B cell maturation 
that is characterized by isotype class switching and somatic hypermutation47. 
Moreover, the support of TFH cells in the germinal center reaction facilitates the 
generation of antibody-secreting, long-lived plasma cells and memory B cells47, 48, 49. 
However, aside of CD4+ T cell differentiation states that mediate immunity, 
suppressive or regulatory CD4+ T cells are also generated in the periphery following 
antigen recognition. Especially the presence of IL-10 or TGFβ in combination with IL-
2 favors the induction of regulatory CD4+ T cells (see paragraph 3.2.3.2.3). 
Additionally to the aforementioned classic T cell subsets, more recent studies 
indicate a role of so-called Th9-differentiated cells in immune reactions against 
parasitic helminth infections50.  
 
 
Fig.  3: T cell subsets. T cell progenitors develop in the thymus into both naïve CD8+ and CD4+ T 
cells as well as CD25+Foxp3+ naturally-occurring regulatory CD4+ T cells. After egress into the 
periphery, CD4+ T cell differentiation after antigen recognition depends substantially on the prevailing 
cytokine milieu. CD4+ T cells can differentiate into effector T cells such as T helper type 1 (Th1) cells, 
Th2 cells, Th17 cells, and follicular helper T (TFH) cells, or develop into regulatory cells such as 
peripherally induced Foxp3+ Treg cells and type 1 regulatory (Tr1) cells. IL: interleukin; TGFβ: 
transforming growth factor beta; RA: retinoic acid. The figure content is based on (51, 52). 
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3.2.3.2 Regulatory CD4+ T cells 
Regulatory T cells (Treg cells) are specialized cells that actively suppress immune 
reactions and their existence had been postulated decades ago53, 54. In 1995, 
Sakaguchi and colleagues identified a fraction of suppressive CD4+ T cells that 
constitutively express the IL-2 receptor α chain (CD25)55. The emergence of 
autoimmune syndromes in neonatally thymectomized mice indicated that these cells 
originated from the thymus56. Later, the transcription factor forkhead box protein 3 
(Foxp3) was identified as an indispensable determinant for the function of these 
regulatory T cells57. Treg cell depletion by anti-CD25 monoclonal antibodies or in 
genetically modified rodents such as Foxp3DTR mice leads to the development of fatal 
and systemic autoimmune disorders. This observation underscores the cardinal 
relevance of Treg cells for the protection from exuberant or misguided immune 
reactions as well as for the prevention of autoimmunity. The development of 
autoimmune disease in Treg cell-depleted adult mice further indicates that Treg cells 
are not only important for the prevention of autoimmunity in neonates, but throughout 
the entire lifetime.  
 
3.2.3.2.1 Development of thymus-derived Foxp3+ Treg cells  
Foxp3+ Treg cells constitute 10 to 15% among peripheral CD4+ T cells in mice and 
can be detected already in the fetal thymus56, 58. The majority of Treg cells  is probably 
generated from cells that already underwent positive selection towards the CD4+ 
lineage59. In addition to TCR ligation, Treg cell development indispensably requires 
CD28-mediated co-stimulation and, moreover, engagement of other receptors that 
belong to the CD28 or tumor necrosis factor receptor superfamily, e.g. cytotoxic T-
lymphocyte antigen 4, programmed death 1, inducible T-cell co-stimulator, or CD40 
ligand60, 61, 62. Similar to conventional CD4+ T cells, Treg cells express a heterodimeric 
αβTCR of equivalent diversity, but, however, remarkably different antigen 
specificity63. TCR repertoire analyses indicate that TCR specificities in the Treg cell 
compartment are, in most instances, absent in the non-Treg cell compartment, 
implying that antigen specificity influences Treg cell lineage commitment63, 64. Once 
controversial, the preponderance of current data supports the hypothesis that self-
reactivity is the primary determinant for thymic Treg cell differentiation65. Treg cell 
development in TCR transgenic mice requires cognate antigen expression in the 
thymus via a second transgene66, 67. Additionally, Treg cells seem to resist negative 
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selection which constitutes the central mechanism for the deletion of self-reactive 
conventional T cells that recognize auto-antigens65. This is consistent with data 
derived from transgenic mice that express GFP in response to TCR stimulation. In 
these mice, GFP was found to be significantly higher in thymic CD4+ T cells that 
express Foxp3 as compared to Foxp3-negative cells, corroborating the hypothesis 
that increased TCR signaling correlates with Treg cell lineage commitment68.  The 
observation that Treg cells compete intraclonally for ligand binding suggests that TCR 
ligands that select Treg cells are presumably rare and tissue-specific rather than 
ubiquitously expressed antigens65. Consistently, a recently characterized TCR 
capable of inducing Treg cell differentiation seems to be specific for a skin antigen69. 
After development and egress from the thymus, Treg cell survival and their 
suppressive function in the periphery strictly relies on the presence of IL-2 signals70, 
71
.  
 
3.2.3.2.2 Forkhead box protein 3 (Foxp3) 
The functional relevance of Foxp3 in vivo becomes apparent in so-called “scurfy” 
mice. A frameshift mutation in these animals leads to a loss of the Foxp3 forkhead 
domain, resulting in a dysfunctional Foxp3 protein. Scurfy mice develop a severe and 
lethal autoimmune syndrome associated with skin inflammation and destruction of 
the dermo-epidermal junctions that became eponymous for the “scurfy” phenotype72. 
In humans, the functional role of Foxp3 is underscored in patients that suffer from 
IPEX (immunodysregulation, polyendokrinopathy and enteropathy, X-linked 
syndrome). In IPEX patients, a variety of mutations in the Foxp3 locus is responsible 
for a dysfunctional Treg cell compartment that leads to the development of a fatal 
multi-organ autoimmune disease73, 74.  
Foxp3 belongs to the forkhead protein family that is involved in a plethora of 
biological functions75. As a member of the forkhead protein subgroup “P”, Foxp3 has 
a forkhead domain as well as both a zinc finger and a leucine zipper motif76. The 
forkhead domain mediates both DNA binding and Foxp3 homo-dimerization. The 
leucine zipper domain mediates homo-dimerization and hetero-multimerization, but is 
also involved in mediating DNA binding77, 78, 79. Between mouse, rat and human, 
Foxp3 homology is about 86%. Mice express one Foxp3 isoform, whereas two 
different Foxp3 isoforms derived from alternative mRNA splicing variants are present 
in men80, 81. Foxp3 is not expressed in murine conventional CD4+ T cells in contrast 
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to humans where the protein can become transiently expressed in activated 
conventional CD4+ T cells that do not exert a regulatory function82, 83.  
The transcription factor Foxp3 regulates about 700 target genes and shows direct 
DNA binding in 10-20%. In most instances, Foxp3 functions as a transcriptional 
repressor, but enhancement of gene expression can also be observed, for instance, 
by increasing cytotoxic T-Lymphocyte antigen 4 (CTLA-4) expression84, 85, 86. 
Mechanistically, Foxp3 is able to recruit histone deacetylases such as histone 
deacetylase (HDAC) 7, or HDAC9, but also histone acetyl transferases such as Tat-
interactive protein 60 kDa (TIP60)87, 88, 89. The recruitment of these enzymes leads to 
acetylation of Foxp3 itself and, moreover, to modifications of the Foxp3 target loci. 
The epigenetic changes of the Foxp3 targets render the chromatin structure 
permissive or repressive, resulting in mRNA expression, or suppression of message 
synthesis90 89. Another important mechanism for Foxp3-mediated suppression of 
gene expression is by hetero-multimerization with other transcription factors such as 
the Nuclear factor of activated T-cells (NFAT), the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) proteins or the acute myeloid leukemia1/ runt-
related transcription factor1 (Aml1/ Runx1)91, 92. Suppression of IL-2 synthesis is 
thereby paradigmatic for this mechanism of gene silencing. In conventional T cells, 
AP-1 and NFAT cooperatively drive the expression of IL-2. In Treg cells, however, 
Foxp3 competes with AP-1 for NFAT binding. As a consequence, the formation of a 
repressive Foxp3/ NFAT complex prevents AP-1/ NFAT binding to the IL-2 locus93. 
Runx1- and NFκB-mediated gene transcription is suppressed in a similar fashion92, 94.  
 
3.2.3.2.3 Induced regulatory CD4+ T cells 
In addition to thymus-derived naturally occurring Treg cells, regulatory cells can arise 
peripherally and develop from conventional Foxp3-CD4+ T cells95, 96. Peripherally 
induced regulatory T cells are considered to play an important role in tolerance 
induction towards foreign antigens such as dietary antigens or antigens derived from 
commensal gut bacteria97. Depending on the cytokine milieu, conventional CD4+ T 
cells differentiate into Foxp3-negative type 1 regulatory T cells (Tr1) that develop in 
presence of IL-10 or IL-2795, 96. Furthermore, Foxp3 can become peripherally induced 
in presence of IL-2 in combination with TGFβ or retinoic acid96, 98, 99. Aside of the 
prevailing cytokine milieu, the most important determinants for peripheral Foxp3 
induction are both TCR affinity and avidity as low avidity TCR engagement by potent 
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ligands accompanied by suboptimal co-stimulation favors Foxp3 induction100, 101, 102. 
Furthermore, inhibitory signals seem to stabilize Foxp3 induction since cytotoxic T-
lymphocyte antigen 4 KO mice exhibit an impaired peripheral Foxp3 induction103. 
 
3.2.3.2.4 Immuno-regulation by Treg cells 
Treg cells are an integral pillar of peripheral tolerance. By actively suppressing 
immune cells, Treg cells are involved in the termination of immune reactions and 
prevent allergy as well as auto-immune diseases104. Mediators such as IL-10, TGFβ, 
IL-35 or galectin-3 have been shown to exert immuno-regulatory functions by acting 
on many different cell types102, 104 (Fig.  4). The cytokines are involved in peripheral 
Treg cell induction denominated as “infectious tolerance”104, 105. Treg cell-derived 
cytokines have been demonstrated to restrain dendritic cell (DC) maturation 
characterized by an attenuated B7 and MHC upregulation102, 105. 
Another Treg cell-mediated mechanism for immuno-suppression of conventional T 
cells is by interfering with the metabolism of the target populations. Thymus-derived 
Treg cells constitutively express the IL-2 receptor α-chain that trimerizes with the 
receptor β- and γ-chain forming a high-affinity IL-2 receptor105. IL-2 constitutes a 
major growth and differentiation factor for all lymphocyte subsets and is primarily 
secreted by conventional T cells. IL-2 deprivation by Treg cells raises the threshold for 
an immune response and may lead to apoptosis induction in weakly activated 
conventional T cells (“metabolic disruption”)102, 105. 
The second messenger cyclic adenosine monophosphate (cAMP) constitutes an 
important mediator involved in peripheral tolerance induction. Treg cells show high 
intracellular cAMP levels and are capable of “injecting” cAMP into cAMP-depleted 
conventional T cells resulting in the repression of cell proliferation and IL-2 
synthesis105. Thymus-derived Treg cells bear the ecto-enzymes CD39 and CD73 on 
their surface metabolizing extracellular ATP and ADP to adenosine105. Engagement 
of the purinergic receptor A2A on conventional T cells by adenosine, in turn, 
provokes an accumulation of intracellular cAMP suppressing T cell effector 
functions102, 105.  
In addition to their suppressive capacity, Treg cells may directly kill responder T cells 
by granzyme- and perforin-dependent mechanisms102, 104, or by releasing apoptosis-
inducing interferon gamma.  Moreover, Treg cells can induce cell death in target cells 
by engaging cell death-inducing receptors by ligands such as Galectin-1 or the TNF-
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related apoptosis-induced ligand (TRAIL) that are both highly expressed in Treg 
cells102, 105. 
One of the most important peripheral tolerance mechanisms represents the 
modulation of APC functions. Full DC maturation is characterized by high expression 
of co-stimulatory molecules which is indispensable for effective T cell priming39. 
Immature or semi-mature DCs, in contrast, exhibit a low expression of co-stimulatory 
molecules and induce T cell anergy, or Foxp3+ regulatory cells. Treg cells have been 
demonstrated to physically interact with DCs restraining their capacity to prime 
conventional T cells. Treg cells express the CD4 homolog lymphocyte activation gene 
3 (LAG3) that engages MHCII molecules on the DC surface to prevent their 
maturation102, 105. The protein receptor CTLA-4 is constitutively expressed on the Treg 
cell surface and competes with CD28 on conventional T cells for the binding of B7102, 
105
. CTLA-4/ B7 interactions can further lead to the trogocytosis of B7 molecules 
resulting in a diminished DC capacity to activate T cells106. Moreover, B7 ligation by 
CTLA-4 induces an upregulation of indoleamine-2,3-dioxygenase (IDO) in DCs which 
catalyzes the conversion of tryptophan to kynurenine102. Tryptophan deprivation 
renders conventional T cells apoptotic, and kynurenine exerts cytotoxic effects on T 
cells adjacent to the IDO-expressing DCs104, 105.  
 
 
Fig.  4: Immuno-suppression by Treg cells. Treg cells harness 3 different kinds of mechanisms to 
suppress non-regulatory T cells (T). First, Treg cells are potent modulators of antigen-presenting cells 
(APC). This includes removal of costimulatory molecules from their surface (1), transmission of 
inhibitory signals by receptor ligation (3), and induction of indoleamine-2,3-dioxygenase (4). Second, 
Treg cells induce apoptosis in target cells in a granzyme- and perforin-dependent or independent 
manner, e.g. by interferon gamma (IFNγ) release (2). Third, Treg cells interfere with the metabolism of 
target cells by releasing immuno-modulatory cytokines (5), by injecting inhibitory molecules such as 
cAMP into target cells (6), or by generating extracellular adenosine (8). IL-2 deprivation by Treg cells 
impedes the expansion of conventional T cells (7). The figure content is based on (102, 104, 107). 
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3.3 Postinfarction healing and remodeling 
The MI-inflicted wound shares many characteristics with injury resulting from trauma. 
In general, healing post-MI is divided into several phases that are orchestrated by the 
immune system. Early after MI, release of inflammatory mediators provoke an influx 
of neutrophils and monocytes into the infarct zone that clear the wound from cell and 
extracellular matrix (ECM) debris to pave the way for the healing phase108, 109, 110. 
During early infarct healing, leukocytes and neo-angiogenic capillary sprouts 
constitute a de novo formed granulation tissue. In parallel, reparative pathways 
become activated promoting the formation of a collagenous scar that ultimately 
replaces the irreversibly injured parenchyma109.  
Remodeling after MI is a dynamic process that accompanies healing over several 
days to weeks111. Ventricular remodeling is characterized by changes in both 
ventricular topography and structure comprising differential alterations in the infarct 
core and the peri-infarct zone. After large MI, an early infarct expansion and 
disproportionate thinning of the left-ventricular (LV) wall provokes an LV dilatation. 
Subsequently, deteriorated cardiac function is compensated by progressive 
hypertrophy in the non-infarct zone that develops over weeks to maintain both blood 
pressure and cardiac output111.   
In parallel to the ventricular remodeling, the extracellular matrix undergoes 
substantial changes that crucially influence global ventricular shape112. An initial ECM 
disruption in the infarct zone promotes an early infarct expansion that is followed by 
the deposition of parenchyma-replacing collagen and de novo ECM construction112, 
113
. In this phase of healing, the ECM turnover rate crucially influences the 
mechanical stability of the emerging scar. Impaired and belated ECM construction or 
an exuberant ECM degradation by collagenolytic enzymes provokes the occurrence 
of infarct ruptures. Collagen-synthesizing fibroblasts gradually differentiate into 
myofibroblasts that acquire contractile functions mediating scar contraction112, 113. 
During late-stage healing, scar tissue maturation is accomplished by cross-linking of 
ECM components. After large MI, however, collagen degradation in the peri-infarct 
zone further promotes a progressive ventricular dilatation that develops over weeks. 
Ultimately, interstitial fibrosis emerges in the peri-infarct zone preserving cardiac 
tensile strength at the expense of ventricular function112. 
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In summary, pronounced LV dilatation and overall cardiac remodeling results in 
fatally deteriorated cardiac function, a disease denominated as congestive heart 
failure characterized by the insufficiency to maintain cardiac output (Fig. 5). 
 
 
 
Fig. 5: Remodeling of the left ventricle (LV) and the extracellular collagen matrix (ECM) after 
myocardial infarction (MI). LV and ECM remodeling are characterized by substantial morphological 
changes extending over several days to weeks. Ultimately, exuberant cardiac remodeling leads the 
development of heart failure describing a state of cardiac pump insufficiency. The figure content is 
based on (112, 113).   
 
 
3.3.1 The relevance of innate immunity in wound healing after MI 
The quality of wound healing and the severity of postinfarction remodeling are 
inevitably linked and pivotally modulated by the immune system. The involved 
leukocyte fractions comprise various classes of myeloid and lymphoid cells that 
mediate both inflammatory and anti-inflammatory reactions. After MI, the leukocyte 
profile in the myocardium changes dramatically and tissue-resident macrophages 
and dendritic cells114, 115 are overwhelmed by infiltrating leukocytes deployed from 
tissues outside of the heart116. 
 
3.3.1.1 Neutrophils 
Shortly after MI, endothelial cells upregulate adhesion molecules like selectins and 
integrins which, along with secreted cytokines, trigger neutrophil infiltration into the 
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infarct zone, resulting in an early neutrophil peak on day 1 after MI in mice117, 118. In 
terms of wound healing after skin injury, neutrophils protect from infections by 
phagocytosis of bacteria and release of cytotoxic mediators like reactive oxygen 
species. In terms of MI, neutrophils contribute to cell debris clearance in the infarct 
zone which constitutes a prerequisite for proper wound healing. Furthermore, 
neutrophils secrete chemokines provoking monocyte recruitment to the site of 
inflammation118, 119. However, neutrophil-derived inflammatory mediators, proteolytic 
enzymes, or reactive oxygen species further harm the cardiomyocytes that have 
survived the ischemic episode118 (Fig. 6). Consistently, experimental neutrophil 
ablation or interference with neutrophil recruitment into the infarct zone reduces the 
infarct size120, 121. Therefore, in terms of cardiac healing, neutrophils are regarded 
deleterious as their functions constitute immunological misfire that targets at 
cardiomyocytes. However, neutrophil numbers wane quickly and, in mice, the 
majority of neutrophils is vanished from the infarct zone three days post-MI117. 
 
3.3.1.2 Mononuclear cells 
Monocytes and macrophages are key players for wound healing after MI122. The 
classic but rather simplistic model proposes that monocytes circulate in the blood and 
trans-differentiate into macrophages upon entry of peripheral tissues123. However, 
the spatial restriction of monocytes and macrophages to defined tissues as well as 
their linear developmental relationship has been revised. Monocytes can develop 
extramedullarily in the spleen, especially during inflammatory conditions such as 
during MI124, 125, 126. Furthermore, tissue-resident macrophages are not necessarily 
derived from blood monocytes but can rather seed peripheral tissues from the yolk 
sac during ontogeny before the onset of hematopoiesis127. Interestingly, these tissue-
resident macrophages have the capacity to self-renew by proliferation in situ128. 
During steady state conditions, the heart harbors very few macrophages. After MI, 
however, macrophage numbers in the infarct zone increase dramatically and both 
monocyte influx and proliferation of pre-existing macrophages may contribute to the 
numerical increase in the infarct zone116.  
The monocyte compartment comprises different monocyte subsets that fulfil a broad 
spectrum of complementary tasks108. Similarly, macrophages show a considerable 
plasticity and the capacity to exert a plethora of biological functions.  
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3.3.1.2.1 Monocytes 
In the steady state, monocytes are generated from hematopoietic stem cells in the 
bone marrow and enter the blood via CCR2129. In mice, monocyte subsets are 
separated on the basis of Ly-6C expression, a GPI-anchored surface protein of 
unknown biological function. 60% of blood monocytes belong to the inflammatory Ly-
6Chigh CCR2high CX3CR1low CD62L+ subset that accumulates preferentially at 
inflammatory sites130. Ly-6Chigh monocytes build up a splenic reservoir in the 
subcapsular red pulp that is rapidly deployed to inflammatory sites such as the 
healing myocardium131. During inflammatory conditions, the frequency of this 
monocyte subset escalates owing to medullary and splenic monocytopoiesis126. After 
homing into peripheral tissues, the cells undergo apoptosis or trans-differentiate into 
macrophages122.     
The Ly-6Clow CCR2low CX3CR1high CD62L- monocyte subset patrols the vasculature 
and accumulates only at low numbers27, 132. So far, the developmental relationship 
between the murine monocyte subsets is not totally clear, but, however, evidence 
suggests that Ly-6Clow monocytes arise from the Ly-6Chigh subset by conversion in 
both blood and bone marrow133, 134, 135. In men, monocyte subsets can be separated 
on the basis of CD14 and CD16 expression, but the functional homology between 
murine and human subsets is still a matter of debate122. 
The Ly-6Chigh monocytes infiltrate the infarct zone during the first days after MI via 
the chemokine receptor monocyte chemotactic protein-1 (MCP-1) and show a 
numerical peak approximately 2-3 days post-MI (Fig. 6). In terms of MI, the two 
monocyte subsets perform complementary tasks in postinfarction healing. Ly-6Chigh 
monocytes secrete inflammatory mediators such as TNFα or ECM-degrading 
proteases. The cells contribute to debris phagocytosis (efferocytosis) and gain the 
initial inflammatory reaction to stimulate reparative pathways108, 117. A large 
proportion of infiltrating monocytes dies within hours in situ, but both medullary and 
splenic monocytopoiesis replenish the continuously high demand of monocytes 
within the infarct region126.  
Successively, monocytes wane from the infarct zone due to apoptosis or 
differentiation into Ly-6Clow macrophages126, 136.   
In contrast to Ly-6Chigh monocytes remains to role of Ly-6Clow monocytes uncertain. A 
former model proposed that monocyte subsets become sequentially recruited to the 
healing myocardium fulfilling complementary tasks117. Ly-6Clow cells were considered 
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to infiltrate the heart in a second wave of monocyte influx to facilitate neo-
angiogenesis or de novo ECM construction108, 117. However, a revised model 
proposes that Ly-6Clow cells in the second phase of healing constitute rather 
terminally differentiated macrophages136 (Fig. 6). In contrast, Ly-6Clow genuine 
monocytes accumulate at very low numbers in the infarct zone. Nevertheless, these 
cells might be crucially involved in postinfarction healing, e.g. by patrolling the 
vasculature, or by marking injured endothelial cells for disposal132, 137.   
 
3.3.1.2.2 Macrophages 
Generally, macrophages are grouped into two distinct subsets, i.e. classically 
activated M1 cells and alternatively activated M2 cells138.  
The classification stems from experiments in vitro showing that bone marrow-derived 
macrophages possess completely different transcriptomes in response to distinct 
cytokines. In presence of lipopolysaccharide or IFNγ, macrophages differentiate into 
M1 cells that have pro-inflammatory characteristics139. M1 macrophages are capable 
of secreting factors such as TNFα, induced NO synthase (iNOS), IL-1β or IL-6. In 
contrast, IL-4, IL-13, IL-10 or TGFβ polarize macrophages towards M2 that express 
inflammation-resolving factors and mediators fostering healing, e.g. TGFβ, 
transglutaminase factor XIII, IL-10, osteopontin or arginase I139, 140, 141, 142, 143, 144. 
However, in vivo, macrophage polarization rather constitutes a continuum between 
the classic M1 and M2 definitions. In terms of inflammation resolution, M1 
macrophages are successively replaced by M2 cells145, 146, 147.  
In the context of MI, the emergence of M1 and M2 mediators in the infarct zone 
follows a biphasic pattern148 (Fig. 6). However, a refined model suggests that Ly-
6Chigh monocytes rather than M1 cells prevail during early infarct healing driving initial 
inflammation136. Subsequently, these Ly-6Chigh monocytes differentiate into Ly-6Clow 
M2-like macrophages that secrete mediators involved in inflammation resolution as 
well as neo-vessel formation and scarring. These monocyte-derived cardiac 
macrophages, in turn, self-renew robustly in situ by local proliferation149.   
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Fig. 6: The role of innate immunity in wound healing after MI. Neutrophils infiltrate the infarct zone 
numerously immediately after MI and amplify the initial local inflammation by secretion of mediators 
such as reactive oxygen species (ROS). Recruited neutrophils secrete collagenolytic enzymes 
(cathepsins and matrix metalloproteinases, MMPs) that promote extracellular collagen matrix (ECM) 
degradation. Neutrophil numbers vane quickly by apoptosis and phagocyte-mediated clearance in situ. 
In the murine system, neutrophils become successively replaced by Ly-6Chigh monocytes that 
accumulate at high numbers in the infarct zone approx. 2 days after MI. These cells further gain the 
inflammation by secreting factors such as TNFα and collagenases. The majority of this monocyte 
subset dies locally by apoptosis, but a proportion differentiates into M1 macrophages that exert pro-
inflammatory functions. During late-stage healing, Ly-6Chigh monocytes downregulate Ly-6C 
expression and differentiate into Ly-6Clow M2-like macrophages. These cells have potent anti-
inflammatory and healing-fostering characteristics as they secrete mediators such as vascular 
endothelial growth factor (VEGF) and transforming growth factor beta (TGFβ) that, among other 
mediators, drives collagen deposition by scar-constructing myofibroblasts. The role of Ly-6Clow 
monocytes for postinfarction healing is unclear so far. The figure content is based on (117, 136). 
 
3.3.2 Activation of adaptive immunity after MI 
The role of innate immunity in cardiovascular pathologies has been studied in great 
detail. In contrast, the relevance of adaptive immunity in the context of 
atherosclerosis, hypertension, and myocardial infarction has been widely 
disregarded. However, experimental studies and clinical trials suggest that T cells 
become also activated after MI. Splenocytes from infarcted rats, for instance, contain 
a subset of CD8+ T cells that show cytotoxic activity against cardiomyocytes in vitro, 
contrary to splenocytes from non-infarcted rats150. Cheng and colleagues found 
Introduction 
24 
 
elevated proportions of IFNγ-producing CD4+ T cells in the blood of infarct patients, 
but no frequency shifts with respect to the expression of IL-4 indicating a Th1/ Th2 
imbalance after MI151. Furthermore, Moraru et al. were able to show that a proportion 
of patients with a recent history of MI showed a proliferative response of peripheral 
blood mononuclear cells to cardiac myosin in contrast to control subjects that did not 
exhibit a cellular reaction152. Consistent with these hints that T cells become 
activated in terms of MI, Abbate and colleagues detected activated T cells in the peri-
infarct zone as well as in the remote myocardium of necroscopy specimen from 
patients that succumbed to acute MI, whereas control hearts did not show an 
accumulation of T cells153. However, although a line of reports implicates that T cells 
are activated in the wake of MI, T cell effector functions or their role in postinfarction 
healing and remodeling have not been systemically addressed.  
A major challenge to decipher T cell priming in human patients arises from the fact 
that the development of atherosclerosis usually precedes the occurrence of MI. 
Atherosclerotic plaque rupture represents the most frequent etiology for MI and 
several plaque components have been demonstrated to serve as T cell antigens. 
Th1- and Th17-polarized CD4+ cells are frequently present in atherosclerotic lesions 
indicating that CD4+ T cells become activated in terms of atherosclerosis154, 155. 
Furthermore, unstable plaques harbor CD28-negative CD4+ T cells that have 
downregulated CD28 due to repetitive stimulation155, 156, implying a state of chronic 
inflammation and T cell activation in the atheroma already before the occurrence of 
MI. As atherosclerosis-related inflammation, thus, may interfere with immune 
reactions provoked by cardiac injury, MI-specific T cell activation cannot be studied in 
man. The (mouse) model of permanent coronary artery ligation, in contrast, provides 
a defined system to study the T cell response in terms of MI independent of 
atherosclerosis-related T cell activation.  
Aside of interfering effects of atherosclerosis on T cell priming and function in 
postinfarction wound healing, recent reports have indicated that CD4+ T cells 
influence post-ischemia reperfusion injury that impacts on healing and remodeling 
secondary to T cell effects on infarct size157, 158. T cell-deficient mice show smaller 
infarcts following an ischemic episode of 45 minutes left coronary artery occlusion as 
compared to T cell-sufficient controls. As the infarct size represents a major 
determinant for the degree of postinfarction remodeling, the influence of T cells on 
healing and, consequently, cardiac remodeling cannot be studied in reperfused 
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hearts. Although the precise mechanism behind this detrimental T cell effect is not 
well understood, it seems that especially CD4+ T cells contribute to reperfusion injury. 
However, by using a (mouse) model of permanent coronary artery ligation, 
reperfusion injury can be obviated allowing a non-ambiguous examination of T cell 
effects on postinfarction healing. 
Aim of the study 
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3.4 Aim of the study 
The role of the innate immune system for wound healing and remodeling after MI has 
been investigated in great detail. In contrast, the contribution of adaptive immunity to 
healing has been widely disregarded. The present study addressed therefore the 
following aspects: 
(1.) Experimental studies and clinical trials implicate that CD4+ T cells become 
activated after MI151, 153. However, so far, the activation of CD4+ T cells in terms of MI 
and their relevance in cardiac wound healing has not been systematically addressed. 
The principal aim of this study was to investigate whether CD4+ T cells become 
activated after MI, and whether T cells influence postinfarction healing and 
remodeling.  
(2.) Healing after MI involves inflammatory and anti-inflammatory reactions. 
Despite the importance of inflammation for early infarct healing, a prolonged or 
accentuated inflammatory response is regarded deleterious. Foxp3+CD4+ Treg cells 
are self-reactive and have potent anti-inflammatory characteristics. The study 
investigated particularly whether Foxp3+ Treg cells become activated in the wake of 
MI and whether these cells modulate cardiac wound healing.  
(3.) Treg cells are involved in the suppression of exuberant immune reactions and 
detrimental auto-immunity. The study investigated whether a therapeutic Treg cell 
activation can be harnessed to improve cardiac wound healing and clinical outcome 
after MI. 
 
Methods and Materials 
27 
 
4 Methods and Materials 
4.1 Materials 
4.1.1 Fine chemicals and reagents 
The following fine chemicals and reagents were used. Unless otherwise specified, all 
substances were acquired from Amersham Biosciences, AppliChem GmbH, 
Calbiochem, Carl Roth GmbH, Gibco BRL/ Life Technologies, Merck, Roche 
Diagnostics, cp-pharma and Sigma-Aldrich. 
Acetone 
Acetic acid 
Alexa488-phalloidin 
Aluminium sulfate 
Ammonium persulfate 
β-mercaptoethanol 
Bovine serum albumin 
Calcium chloride 
Citric acid 
DAPI (4',6-diamidino-2-phenylindole) 
Diphtheria toxin 
Disodiumhydrogenphosphate 
DMSO 
Dry mild, fat-free 
EDTA 
Eosin 
Ethanol 
FCS (fetal calf serum) 
Glycin 
Glycerol 
Hematoxylin 
Heparin 
Isopropyl alcohol 
Isoflurane  
Luminol 
Magnesium chloride 
Magnesium sulfate 
Methanol 
L-glutamine 
Liquid nitrogen 
Paraformaldehyde 
Rotihistol 
Sirius red (Direct red 80) 
Sodium azide 
Sodium chloride 
Sodiumdihydrogenphosphate 
Sodium pyruvate 
Paraffin Medite Tissuewax 
Picric acid 
Ponceau S 
Potassium chloride 
Sodium azide 
Tetramethylethylenediamine (Temed) 
Tris (Tris(hydroxymethyl)aminomethane) 
Trypan blue 
Tween 20 
4-Hydroxycoumarin 
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4.1.2 Antibodies 
Fluorophore- and biotin-labeled FACS antibodies directed against mouse 
antigens 
 
 Antibody       Supplier 
anti-CD11b-PE (M1/70)     eBioscience 
anti-CD45-efluor 450 (clone 30-F11)   ebioscience 
anti-F4/80-FITC (clone BM8)    eBioscience 
anti-Foxp3-PE-Cy5.5 (FJK-16s)    eBioscience 
anti-Ly-6C-PerCP-Cy5.5 (clone HK1.4)   eBioscience 
anti-CD4-Alexa647 (clone RM4-5)   BioLegend 
anti-CD8a-Pe-Cy7 (clone 53-6.7)    eBioscience 
anti-Helios-Pacific Blue (clone 22F6)   BioLegend 
anti-CD19-Biotin (clone 6D5)    BioLegend 
anti-Ly-6G-Alexa647 (clone 1A8)    BioLegend 
anti-Ki67-PE (clone B56)     eBioscience 
anti-CD3ε-Pe-Cy7 (clone 145-2C11)   BioLegend 
anti-TNFα-BV421 (clone MP6-XT22)   BioLegend 
anti-IFNγ-PE (clone XMG1.2)    BioLegend 
anti-CD19-biotin (clone 6D5)    BioLegend 
anti-CD25-PE (clone PC61)    BioLegend 
 
Primary antibodies used for Western blot, immunohistochemical and 
immunofluorescence stainings directed against mouse antigens: 
   
 anti-alpha smooth muscle actin (clone 1A4)  Dako 
anti-collagen type I (polyclonal)    Cedarlane 
anti-collagen type III (polyclonal)    Cedarlane 
anti-Foxp3 (clone FJK-16s)    eBioscience 
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Secondary antibodies for Western blot and immunofluorescence stainings: 
 
goat-anti-rat IgG-HRP (polyclonal)   Santa Cruz 
goat-anti-rat IgG-Alexa 555 (polyclonal)   Molecular Probes 
 
4.1.3 Buffers and solutions 
All buffers and solutions were prepared in desalted water.  
 
PBS      NaCl (pH 7.4)   137 mM 
Na2HPO4    10 mM 
KCl     2.6 mM 
KH2PO4    1.8 mM 
 
FACS buffer   NaCl (pH 7.4)   137 mM 
Na2HPO4    10 mM 
KCl     2.6 mM 
KH2PO4    1.8 mM 
BSA     0.1% (w/v) 
NaN3     0.1% (w/v) 
 
Laemmli buffer  Tris-HCl (pH 6.8)   125 mM 
SDS     4% (w/v) 
Glycerol    20% (v/v) 
2-mercaptoethanol   10% (v/v) 
Bromophenol blue   0.004% (w/v) 
 
BSS/ (BSA)   KCl    5.33 mM 
    KH2PO4   0.44 mM 
    NaCl    138 mM 
NaHCO3   4 mM 
Na2HPO4   0.3 mM 
     (BSA)    (5%) 
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Erythrocyte   NH4Cl    150 mM 
lysis buffer   NaHCO3   10 mM 
EDTA    0.15 mM 
 
SDS-PAGE   Tris-HCl (pH 8.5)  25 mM 
running buffer  Glycine   192 mM 
SDS    0.1% (w/v) 
 
Transfer buffer  Tris-HCl (pH 8.3)  25 mM 
     Glycine   192 mM 
     Methanol   20 % (v/v) 
 
TBST    Tris-HCl (pH 7.6)  50 mM 
     NaCl    150 mM 
     Tween 20   0.05% (v/v) 
 
 Blocking buffer  TBST  
Fat-free dry milk   5% 
 
Detection reagent  Tris-HCl (0.1M, pH 8.6) 200 ml 
 Solution A   Luminol   50 mg 
 
 Detection reagent   DMSO   10 ml 
 Solution B   4-Hydroxycoumarin  11 mg  
 
 Stripping buffer  Tris-HCl (pH 6.8)  65 mM 
     SDS    2% (w/v) 
     2-mercaptoethanol  100 mM 
 
 Neutral-buffered  Formaldehyde   3.7% 
formaline   Na2HPO4    46 mM 
NaH2PO4   29 mM 
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Mayer´s Hematoxylin Acetic acid   2% 
     Glycerol   30% 
     Hematoxylin   1% 
     Aluminium sulfate  5% 
 
 Picro-sirius red  Picric acid   1.5% 
     Sirius red   0.1% 
 
4.1.4 Ready for use kits and solutions 
 
Kit        Supplier 
ARK™ peroxidase kit     Dako 
CD3ε MicroBeat kit      Miltenyi 
Cytometric Bead Array     BD 
Entellan       Merck 
Foxp3 Transcription Factor Staining Buffer Set  eBioscience 
Quantikine ELISA Mouse/ RAT Osteopontin   R&D 
Quantikine ELISA Mouse IL-13    R&D 
Quantikine ELISA Mouse TGF-beta 1   R&D 
RNeasy Micro Kit      Qiagen 
RNeasy Mini Kit      Qiagen 
Trinucleotide mRNA amplification Pico Kit  AmpTec 
DNase 1, Amplification Grade, AMP-D1   Sigma 
iScript cDNA Synthesis Kit     Bio-Rad 
Ladewig staining solution kit     Morphisto 
Protein Extraction Reagent Type 4   Sigma 
RNAlater Solution      Ambion 
TaqMan Master Mix     Life Technologies 
Vectashield mounting medium    Vector Laboratories 
3,3'-diaminobenzidine solution    Abcam 
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4.1.5 TaqMan probes 
All probes for Real-time RT-PCR analyses were purchased from Life Technologies. 
 
Gene       Probe number  
Arginase I      Mm00475988_m1 
TGFβ1      Mm01178820_m1  
Alpha smooth muscle actin   Mm00725412_s1 
TIMP-1      Mm00441818_m1 
TIMP-2      Mm00441825_m1 
MMP-2      Mm00439498_m1 
MMP-9      Mm00442991_m1 
Osteopontin      Mm00436767_m1 
FXIIIa       Mm00472334_m1 
GAPDH      Mm99999915_g1 
Collagen alpha 1 (type 1)    Mm00801666_g1 
Collagen alpha 1 (type 3)    Mm01254476_m1 
iNOS       Mm00440488_m1  
Interleukin-10     Mm00439615_g1 
Interleukin-13     Mm00434204_m1 
Interleukin-1β     Mm0043228_m1 
Interleukin-6      Mm00446190_m1 
TNFα       Mm99999068_m1 
IFNγ       Mm01168134_m1  
 von Willebrand factor    Mm00455669_m1 
Vimentin      Mm01333430_m1 
 
4.1.6 Antibodies, ligands, and fine chemicals for cell culture 
 
 Chemical      Supplier 
 Human TGFβ1     BioLegend 
 Mouse Interleukin-10    BioLegend 
 Mouse Interleukin-13    Biolegend 
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Human Interleukin-2 (Proleukin)   Novartis  
Anti-mouse-TGFβ (clone 1D11)   R&D 
 CD28-SA      Exbio 
 Dynabeads Pan Mouse IgG   Life Technologies 
 Monensin 1000x     BioLegend 
 Penicillin/ Streptomycin    Gibco 
 Phorbol 12-myristate 13-acetate (PMA)  Sigma 
 Streptomycin     Invitrogen 
 Ionomycin       Sigma 
  
4.1.7 Enzymes 
Collagenase Type 2     Worthingon 
 DNase I      Sigma 
 
4.1.8 Animals 
All mice were between 8-10 weeks old at the day of surgery. Transgenic and knock-
out mice had a C57BL/6 background and wildtype littermates were used as reference 
controls. The study conformed to the regulations for animal experiments and was 
approved by the local government.  
 
 Mouse strain     Supplier 
 Wildtype C57BL/6J     Harlan or Jackson Laboratory 
 MHCII KO      Jackson Laboratory 
OT-II       Jackson Laboratory 
DEREG      Jackson Laborator 
4.1.9 Consumables 
Consumable      Supplier 
Catheter Vasofix Safety    Braun  
Cell separation columns    Miltenyi 
Cell strainer (70 and 100 µm mesh)  BD Biosciences 
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Centrifuge tubes     Greiner 
Cover slips 24 x 50mm    Menzel  
Cryo tube (1.8 ml)     Nunc 
Entellane      Merck 
FACS tubes      BD 
Filter paper      Whatman 
Microseal film for PCR plates   Bio-Rad 
Microtome blades S35 Typ    Feather  
Needles (25 gauge and 19 gauge)   Braun 
Nitrocellulose transfer membrane   Whatman 
Object slide, SuperFrost Ultra plus  R. Langenbrinck   
PageRuler Prestained Protein Ladder  Fermentas 
PCR tubes (0.2 ml)     Eppendorf 
Pipette tips (10 µl, 200 µl, 1000 µl)  Starlab 
Polypropylene suture (0.7 metric)   Vömel 
Reaction tubes (1.5 ml and 2 ml)   Eppendorf 
Scalpel       Hartenstein 
Serological pipettes     Greiner 
Sterile Filter (0.45 µm)    Machery-Nagel 
Tissue culture dishes (35 mm)   Greiner  
Tissue Ruptor Disposable Probes   Qiagen 
Tissue-Tek O.C.T. compound   Sakura    
96-well plates (U-bottom, V-bottom)   Greiner/ Nunc/ Ratiolab 
96-well PCR plates     Bio-Rad 
 
4.1.10 Instruments 
Analytical balance     Kern 
Biofuge Fresco     Heraeus 
Block heater      Biosan 
Centrifuge 5810 R     Eppendorf 
Cell sorter FACS Aria III    BD Biosciences 
ELISA-Reader, MRX tc    Dynex 
Flow cytometer LSR II    BD Biosciences  
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Fluorescence microscope Axio imager Z1m Zeiss  
iCycler       Biorad 
Incubator, Hera cell 150    Thermo Scientific 
Isoflurane Vaporizer     Harvard Apparatus 
Laminar flow hood     Heraeus 
Light-optical microscope Axioskop 2 plus  Leica Microsystems 
Magnetic stirrer     Labinco 
Microtome Hn40     Reichert-Jung 
Paraffin embedding station    Bavimed 
Pipettes      Eppendorf 
Power supply PowerPac 2000   Bio-Rad 
pH meter      WTW 
Qubit Fluorometer     Life Technologies 
Thermocycler      Eppendorf 
Tissue Ruptor      Qiagen 
Ultrasound instrument (Aplio System)  Toshiba    
Vortex mixer      Labinco 
Western blot chamber    Bio-Rad 
Western blot scanner C-DiGit   LI-COR 
2100 Bioanalyzer     Agilent 
 
4.1.11 Electronic data processing 
Data acquisition, analysis and presentation were performed using the following 
software on diverse Windows-operated personal computers provided by Fujitsu-
Siemens: 
 
Adobe Photoshop CS3    Microsoft Word 2007  
BD FACSDiva 5.0     Systat Software SigmaScan 
ImageJ      Thomson EndNote 9.0 
GraphPad Prism 4.03    TomTec Image Arena 
Microsoft Excel 2007    Tree Star FlowJo 8.8.6 
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4.2 Methods  
4.2.1 In vivo experiments 
4.2.1.1 Surgeries 
Mice were anesthetized in a chamber containing a 2% isoflurane atmosphere, placed 
in a supine position, intubated and ventilated with 100% oxyxen supplemented with 
0.8% isoflurane to sustain anaesthesia. The paws were taped to the operation table 
the chest opened using a midline sternotomy to expose the heart. A nylon suture was 
passed under the left anterior descending coronary artery using a tapered needle to 
place the ligature. After artery occlusion, the chest was closed. For sham operations, 
thoracotomy was conducted without subsequent coronary artery ligation. For pre-
emptive analgesia, buprenorphine was routinely administered after surgery. 
Operations were conducted by Charlotte Dienesch and Barbara Bayer.  
 
4.2.1.2 Treg cell depletion in DEREG mice 
Treg cells were depleted by using “depletion of regulatory T cell (DEREG)” mice that 
specifically express the human diphtheria toxin receptor (DTR) in Foxp3-positive 
cells159. All experiments were conducted utilizing a distinct strain of DEREG mice that 
had been generated by using a Foxp3 targeting vector159. Treg cells were depleted 
before MI induction by intraperitoneal administration of 500 ng diphtheria toxin (DTX) 
on day 2 and day 1 before surgery. To prevent a rebound of Treg cells, 250 ng DTX 
were injected on day 2 and day 4 after MI induction.  
 
4.2.1.3 Antibody-mediated depletion of Foxp3+CD4+ Treg cells 
Depletion was achieved by administration of a rat anti-mouse CD25 monoclonal 
antibody labeling thymus-derived Treg cells that constitutively express high levels of 
CD25 on their cell surface. 1 mg anti-CD25 antibody (clone PC61) were injected 
intraperitoneally 8 day prior to MI induction to effectuate Treg cell depletion by 
phagocytes160, 161.     
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4.2.1.4  Treg cell activation in vivo 
Treg cell expansion was conducted by a single intraperitoneal injection of a 
superagonistic anti-CD28 monoclonal antibody (CD28-SA) that cross-links CD28 
molecules on the T cell surface provoking a vigorous activation signal162, 163. As Treg 
cells are highly responsive to CD28-SA stimulation, the CD28-SA was administered 
at low dose of 300 µg per mouse to elicit a net expansion of Treg cells over 
conventional T cells.  
 
4.2.1.5 IL-2/ anti-IL-2 monoclonal antibody (mAB) complex treatment 
Recombinant murine IL-2 (PeproTech) was mixed with anti-IL-2 monoclonal antibody 
(clone JES6-1, eBioscience) in 0.9% sterile NaCl solution and incubated for 30 min at 
room temperature. IL-2 and anti-IL-2 mAB were mixed at a molar ratio of ~2:1164. 
Each mouse was treated on three consecutive days receiving a dose of 6 µg IL-2/ 
anti-IL-2 mAB complexes per injection (1 µg IL-2 and 5 µg anti-IL-2) corresponding to 
approximately 5000 IU IL-2 per day and mouse164, 165.  
 
4.2.1.6  Echocardiography 
Mice were anesthetized in a chamber containing a 2% isoflurane atmosphere. After 
immobilizing the mice in a supine position, the snout was placed in a nose cone 
connected to the anesthesia system. Steady-state sedation level was maintained 
using 0.4% to 0.6% isoflurane mixed with 0.5 L/min 100% oxygen. Cardiac 
ultrasound analysis was performed on a Toshiba Aplio system. After shaving the 
chest, ultrasound gel was applied and the probe lowered parasternally onto the 
thorax for short-axis echocardiographic measurements at both the level of the mid-
papillary muscles and the apex. Anesthesia was adjusted to obtain a target heart rate 
higher than 500 beats per minute. 
Two-dimensional imaging of the left ventricle was conducted and both luminal end-
diastolic and end-systolic area (EDA, ESA) were assessed. To obtain fine 
measurements of luminal diameters and the wall thickness, transversal M-mode 
echocardiography was performed providing a 1-dimensional view of the left-
ventricular (LV) luminal diameter and both the anterior and posterior wall thickness. 
All measurements were conducted both at the papillary and the apical level. Images 
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were analyzed using Image Arena (TomTec). To assess left-ventricular contractile 
function, LV fractional shortening (FS) was determined using the following formula166:  
 
FS (%) = 100 x [(EDD – ESD) / EDD]  
   FS: fractional shortening 
   EDD: end-diastolic diameter (left-ventricular lumen) 
   ESD: end-systolic diameter (left-ventricular lumen) 
 
Echocardiography measurements were performed by Sandra Umbenhauer and 
Barbara Bayer.  
4.2.2 Organ preparation 
Infarcted mice were anesthetized and injected with heparin (40 IU per mouse) to 
prevent blood clotting. After thoracotomy, blood vessels were depleted from blood by 
perfusing the vascular system with ice cold PBS. After perforation of the right 
ventricle, a cannula was inserted into the left ventricle and the PBS slowly injected. 
The mouse was perfused with approximately 10 ml PBS until the tissues became 
“pale”. After heart excision, the right ventricle was removed and the left-ventricular 
infarcted apex dissevered. Depending on the analysis, the tissue was processed 
differently. For protein analysis, a part of the apex was transferred into a tube for 
cryo-conservation, frozen in liquid nitrogen and stored at -80°C. For mRNA 
expression analyses, a part of the infarcted tissue was incubated overnight at 4°C in 
RNAlater (ambion). After incubation, the tissue was transferred into a tube for cryo-
conservation and stored at -80°C. For flow cytometry analyses, the tissue was 
minced and digested with collagenase type 2 (1000 IU/ml) and DNase I (60 IU/ml) for 
35 min at 37°C. The remaining tissue pieces were grinded against a cell strainer of 
100 µm pore size to obtain a single cell suspension.  
Transversal left-ventricular cross-sections adjacent to the cardiac apex were used for 
histochemical and immunofluorescence stainings. For histochemistry, tissue was 
incubated in 4% formaldehyde solution for fixation. For immunofluorescence 
stainings, the tissue was embedded in Tissue-Tek providing a specimen matrix and 
stored at -80°C.   
Spleen and lymph nodes were collected in BSS/ BSA. Single cell suspensions were 
generated by grinding the organ against a cell strainer of 40 µm pore size. To deplete 
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erythrocytes from splenic suspensions, cells were treated with erythrocyte lysis buffer 
for 2 min and washed with BSS/ BSA.  
For final blood analyses, samples were collected by puncture of the heart after 
thoracotomy before perfusion of the vascular system. For evaluation of antibody 
treatments, mice were narcotized with isofluorane and blood collected by inserting a 
heparin-filled cannula into the venous plexus behind the eye. Erythrocytes were 
eliminated by incubation in erythrocyte lysis buffer for 10 min and subsequently 
washed with BSS/ BSA.  
 
4.2.3 Cell culture 
Generally, primary cells were incubated in an atmosphere containing 5% CO2 at 
37°C. Cells were cultivated in supplemented RPMI medium from Gibco. 
 
 RPMI medium, supplemented with 10% FCS 
       2 mM L-glutamine 
       1 mM sodium pyruvate  
       100 U/ ml penicillin/ streptomycin 
       50 µM 2-mercaptoethanol 
 
Cells were pelletized by centrifugation at 500 g at room temperature. Cell numbers 
were assessed using a Neubauer hemocytometer by mixing 10 µl cell of suspension 
with 10 µl Trypan blue to distinguish dead from vital cells.    
 
4.2.4 Immunological methods 
4.2.4.1 Flow cytometry  
Flow cytometry is a laser-based technology for cell counting, cell sorting and 
evaluation of protein expression on a per-cell basis. During measurements, a cell 
suspension streams through a detection apparatus performing a multi-parameter 
analysis. Different lasers are directed on the suspension stream exciting fluorescent 
dyes that label the cell components of interest. The combination of scattered and 
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fluorescent light, in turn, provides information about the analyzed cell type and 
expression levels of targeted proteins.  
Up to 106 cells were suspended in 50 µl FACS buffer containing anti-CD16/ CD32 
monoclonal antibody (clone 2.4G2, 1:400) to block unspecific Fc-receptor binding. 
After blocking at 4°C for 15 min, fluorophore-conjugated antibodies were added to 
the cell suspension and incubated for 15 min at 4°C. The Foxp3 / transcription factor 
staining buffer set (eBioscience) was used for intracellular staining. Cells were fixed 
by 30 min incubation in fixation buffer at room temperature. After washing in 
permeabilization buffer, cells were incubated for 30 min at room temperature in 
presence of fluorophore-labeled antibodies directed against intracellular targets 
diluted 1:50 in permeabilization buffer. In order to stain cytokines intracellularly, cells 
were incubated for 6 hours in presence of ionomycin (1µg/ ml, Sigma), phorbol-12-
myristate-13-acetate (PMA, 50 ng/ ml, Sigma) and monensin (1:1000, BioLegend) 
before staining. Finally, cells were washed, resuspended in FACS buffer and 
analyzed on an LSR II flow cytometer (BD Biosciences). FlowJo (TreeStar Inc) was 
used for data analysis. Plots are shown as log10 fluorescence intensities.  
 
4.2.4.2 Fluorescence-activated cell sorting (FACS) 
FACS is a special type of flow cytometry and constitutes a method to sort a 
heterogeneous cell suspension based on cell-specific light scattering and 
fluorescence characteristics. The cell suspension stream is arranged in a way to 
guarantee a large interspace between individual cells relative to their diameter. A 
vibrating mechanism causes the flow to break into droplets containing single cells. 
Before droplet formation, fluorescence and scattered light from the cells are 
measured. Droplets containing cells of interest are charged and, thereafter, sorted by 
an electrostatic deflection system.   
 
4.2.4.3 Enzyme-linked Immunosorbent Assay (ELISA) 
In order to evaluate bio-molecule concentrations in cell culture supernatants, an 
enzyme-linked immunosorbent assay (ELISA) of the “sandwich” type was used. For 
all experiments, ELISA kits from R&D were used according to the manufacturer´s 
protocol. In sandwich ELISAs, capture antibodies are non-covalently coated to 
polysterene plates via the hydrophobic Fc-region of the immunoglobulin molecule. 
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After blocking, diluted cell culture supernatants were added to the wells and 
incubated for 2 hours. For analysis of TGFβ1 concentrations, samples were pre-
treated with 1N HCl to reveal antibody binding sites before the supernatants were 
added to the wells. After extensive plate washing, biotinylated detection antibodies 
were added to the wells and incubated for another 2 hours. After 5 additional 
washing steps, horseradish peroxidase (HRP)-conjugated streptavidin was added. 
For detection of antigen-antibody complexes, the HRP substrate 
tetramethylbenzidine was supplemented resulting in chromogen conversion into a 
blue chromophore. The reaction was stopped after 30 min of incubation by addition 
of sulphuric acid converting the color to yellow. Extinction was measured at 450 nm 
using a 96-well plate ELISA reader (Dynex MRX Revelation TC 96).             
 
4.2.4.4 Magnetic cell separation (MACS) 
To enrich monocytic cells from lymphoid organs, lymphocytes were depleted from 
single cell suspensions derived from spleens as well as inguinal, axillary, brachial, 
cervical and lumbar lymph nodes. To this end, the CD3ε MicroBeat kit from Miltenyi 
was used in a modified protocol. 108 cells per ml BSS/ BSA were blocked for 15 min 
on ice using 2.4G2 blocking antibody (1:400) and incubated in presence of both 
biotinylated anti-mouse CD3ε (dilution 1:10) and biotinylated anti-mouse CD19 
(dilution 1:300). After 15 min incubation on ice, cells were washed and, subsequently, 
1.2 x 108 cells per ml BSS/ BSA magnetically labeled using anti-biotin microbeads 
(dilution 1:5). After 10 min incubation on ice, cells were washed in BSS/ BSA and 
loaded onto an LS-MACS column placed in the magnetic field of a MACS separator. 
After rinsing the column with 9 ml BSS/ BSA, negatively-selected cells represented 
the lymphocyte-depleted monocyte/ macrophage enriched fraction.   
   
4.2.5 Molecular biology 
4.2.5.1 RNA isolation 
RNA from tissue or primary cells in culture was isolated using the RNeasy Mini kit 
(Qiagen) or the RNeasy Micro kit (Qiagen), respectively. After tissue or cell 
homogenization in lysis buffer, samples were spun for 3 min at 8.000 g at room 
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temperature to pelletize hydrophobic constituents. The aqueous phase containing the 
hydrophilic RNA was mixed with one volume 70% ethanol in water and transferred 
onto the RNA-binding silica-membrane spin columns. After centrifugation at 8.000 g 
for 15 sec, RNA was purified on-column using the provided washing buffer. RNA was 
eluted in 40 µl nucleic acid-free water and stored at -80°C.  
 
4.2.5.2 RNA quantification 
4.2.5.2.1 Fluorometric RNA quantification 
RNA concentrations were determined using the Qubit fluorometer (Life 
Technologies). Generally, the method exploits fluorescent dyes that show a weak 
fluorescence before binding to their specific target, i.e. nucleic acids or proteins. 
Dyes in complex with their target increase their fluorescence intensity by several 
orders of magnitude linearly reflecting the amount of bulk RNA or protein within the 
sample.  
 
4.2.5.2.2 Bioanalyzer measurement  
The Bioanalyzer (Agilent) is a microfluidics-based platform to evaluate quality, 
amount and size of RNA. The RNA is electrophoretically separated by size in a gel 
matrix. Dye molecules intercalate into RNA strands and are subsequently detected 
by laser-induced fluorescence proportional to the amount of RNA. Data is translated 
into gel-like images or electropherograms.   
 
4.2.5.3 DNA digestion 
To eliminate DNA contaminations in RNA solutions, DNA was digested using the 
AMP-D1 kit (Sigma). Up to 1 µg total RNA was mixed with 1 µl reaction buffer and 1 
µl DNase I solution. The volume was adjusted to 10 µl using nucleic acid-free water 
and the sample was incubated for 10 min at room temperature. After addition of 1 µl 
stop solution, the sample was incubated at 70°C for 10 min.  
 
4.2.5.4 Reverse transcription of RNA 
Copy DNA (cDNA) is synthesized by reverse transcription from an RNA matrix. For 
cDNA generation, the iScript cDNA synthesis kit (Bio-Rad) was used. 1 µg RNA was 
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mixed with 4 µl nuclease free-water, 4 µl reaction buffer and 1 µl reverse 
transcriptase. The volume was adjusted to 20 µl and cDNA synthesis conducted in a 
thermo cycler using the following program:  
 
     5 min   25°C 
     30 min 42°C 
     5 min  85°C 
     5 min  4°C 
 
The cDNA was stored at - 20°C for further experiments. 
 
4.2.5.5 Real-time (RT) polymerase chain reaction (PCR) 
Real-time RT-PCR is a technique to quantify the amount of DNA within a sample. 
The reaction is conducted in a thermal cycler with capacity to illuminate the sample 
and simultaneously detect the fluorescence from an excited fluorophore. The PCR 
process generally consists of a series of temperature changes. In a first step (50°C), 
uracil-N-glycosylase treatment prevents re-amplification of potential carry-over PCR 
products by removing any uracil incorporated into single- or doublestranded 
amplicons. After cDNA denaturation at 95°C, temperature decreases to 60°C for 
primer annealing and DNA strand elongation.  
For Real-time RT-PCR analyses, target-specific TaqMan probes (Life Technologies) 
containing forward and reverse primers were utilized. The commercially available 
TaqMan Master Mix (Life Technologies) provides the Taq polymerase and 
deoxynucleoside triphosphates. Reagents were used according to the 
manufacturer´s protocol:  
 
    Master Mix 12.5 µl 
    Probe  1.25 µl 
    H2O  6.25 µl 
    cDNA  5 µl containing 5-20 ng cDNA 
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The following program was used for PCR reaction: 
 
     50°C  2 min 
     95°C  10 min 
     95°C   15 sec 
     60°C  1 min 
 
DNA quantification was performed during strand polymerization using fluorescent 
reporter probes that bind specifically to the target gene. The probes are couples to a 
fluorescent dye at the 5´ probe end and a quencher at the 3´ probe end suppressing 
reporter fluorescence. During strand elongation, the DNA polymerase-intrinsic 5´ to 
3´ exonuclease activity catalyzes probe breakdown resulting in a spatial dissociation 
of the quencher from the reporter. The released reporter, in turn, can become excited 
to fluoresce. Increasing amplicon amounts, thus, lead to a proportional increase of 
fluorescence intensity. A threshold for the detection of reporter fluorescence is set 
slightly above the background signal and the number of cycles at which the 
fluorescence exceeds the threshold is denoted as threshold cycle (Ct). Relative 
quantification of gene expression was performed by using the ∆Ct-method, i.e. a 
normalization of the target gene Ct value to the Ct value of the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Relative expression changes 
are presented as 2-∆Ct. 
 
4.2.5.6 RNA in vitro transcription  
RNA in vitro transcription constitutes a method to amplify small amounts of RNA. 
Generally, the RNA is reversly transcribed into copy DNA (cDNA) that serves as 
matrix for the subsequent RNA transcription. For gene expression analysis in sorted 
or cultivated monocytes, the isolated RNA was amplified by two rounds in vitro 
transcription using the TRinucleotide mRNA amplification Pico Kit (amptec) according 
the manufacturer´s protocol. Briefly, isolated RNA was reversly transcribed into 
cDNA. After DNA purification on the provided silica matrix-based spin columns, RNA 
was synthesized overnight by in vitro transcription of the cDNA. After RNA 
purification using silica gel matrix spin columns, a second round of cDNA 
transcription and RNA synthesis was performed to further increase RNA yield.  
40x 
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4.2.6 Protein biochemistry 
4.2.6.1 Protein extraction and assessment of protein concentration 
Scar tissue was homogenized in Protein Extraction Reagent Type 4 (Sigma). After 
centrifugation at 8000 g and 4°C for 10 min, the supernatant was used for 
subsequent analyses. Protein was quantified using the Qubit fluorometer (see 
above). Samples were stored at -80°C.  
 
4.2.6.2 Electrophoretic protein separation (SDS-PAGE) 
Proteins were separated in a polyacrylamide gel electrophoresis (PAGE) on the basis 
of their molecular weight.  Gels were produced according to the following formulae:  
 
Stacking gel (5%):  ddH2O     4.1 ml 
    30% acrylamide    1 ml 
    1M Tris (pH 6.8)    0.75 ml 
    10% Sodium dodecyl sulfate (SDS) 0.06 ml 
    10% ammonium persulfate  0.06 ml 
    TEMED     0.006 ml 
 
Resolving gel (15%): ddH2O     4.6 ml 
    30% acrylamide    6 ml 
    1.5M Tris (pH 8.8)    3.8 ml 
    10% SDS     0.15 ml 
    10% ammonium persulfate  0.15 ml 
    TEMED     0.006 ml 
  
Gels were manufactured in a Mini-gel chamber from Bio-Rad. At first, the resolving 
gel was polymerized between the two glass plates and covered with isopropyl 
alcohol. The stacking gel was loaded onto the resolving gel and inserted with a comb 
to spare the sample pockets. The chamber was filled with running buffer and 
samples were loaded into the pockets. Voltage was set to constant 100V. Separation 
was stopped when the resolution was adequate in the region of interest.  
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4.2.6.3 Sample preparation for SDS-PAGE 
20 µg of total protein were boiled for 5 min at 95°C in Laemmli buffer containing β-
mercapthoethanol (β-ME). The high temperature, β-ME and SDS assured protein 
denaturation and breakdown of the disulfide bridges. After protein unfolding, the 
anionic SDS molecules bind to the polypeptides and outweigh their intrinsic charge. 
The mechanism safeguards protein separation according to their molecular mass, 
and not due to interfering effects of protein-intrinsic charge. As the gel constitutes a 
micro-sieve, small proteins wander at higher velocity along the electric field as 
compared to higher molecular proteins. As a consequence, proteins are separated 
according to their molecular mass.   
 
4.2.6.4 Western blot and protein detection 
SDS-PAGE-separated proteins were transferred from the gel onto a nitrocellulose 
membrane by so-called “semi-dry” blotting. Filter papers, membrane and gel were 
equilibrated in transfer buffer and stacked within a transfer chamber that was 
energized at constant 20V. The transfer was stopped after 120 min and transfer 
efficiency evaluated by unspecific protein staining using Ponceau S.  
Target proteins on the membrane were specifically detected by antibodies. To 
prevent unspecific antibody binding, the membrane was blocked in 5% non-fat dry 
milk in TBST (w/v) for 1 hour. The membrane was incubated overnight at 4°C in 5% 
nonfat dry milk/ TBST containing the primary antibody diluted to a concentration 
according to the manufacturer’s recommendation. After three 10 min washing steps 
in TBST, a horseradish peroxidase (HRP)-conjugated secondary antibody directed 
against the primary antibody was diluted in TBST and incubated with the membrane 
for 1 hour. After 5 additional 5 min washing steps, the membrane was incubated in a 
detection reagent containing luminol that emits light during HRP-mediated cleavage. 
The detection reagent was mixed immediately before usage (1 ml solution A, 100 µl 
solution B, 0.3 µl H2O2). Chemoluminescence was detected using a LI-COR C-DiGit 
luminescence scanner.  
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4.2.6.5 Membrane stripping 
In order to detach antibodies, the membrane was incubated for 20 min in stripping 
buffer at 50°C. After washing in TBST, the membrane was blocked again in TBST/ 
5% non-fat dry milk and, subsequently, incubated with a primary antibody.  
 
4.2.7 Optical imaging 
4.2.7.1 Immuno-/ histochemical stainings on paraffin sections  
4.2.7.1.1 Preparation of paraffin sections 
After fixation for 24 hours in 4% formaldehyde, the tissue was put into a tissue 
cassette and dehydrated by successively increasing ethanol concentrations in the 
tissue environment. Subsequently, ethanol was replaced by xylene and ultimately by 
paraffin. The following dehydration protocol was used:       
 
1. 70 % ethanol: 1 h  
2. 90 % ethanol: 1 h 
3. 96 % ethanol: 5 h 
4. 50:50 xylol:ethanol: 1 h 
5. 100 % xylol: 1,5 h  
6. 100 % xylol: 1,5 h 
7. 50:50 xylol:paraffin: 1 h at 60°C 
8. 100 % paraffin: 1,5 h at 60°C 
9. 100 % paraffin: 3 h at 60°C 
 
Eventually, tissue was embedded in liquid paraffin at 68°C for conservation. After 
paraffin curing at room temperature, tissue blocks were sliced into 5 µm and 7 µm 
sections using a microtome and transferred onto glass slides. Paraffin sections were 
deparaffinized and rehydrated by successively decreasing the content of organic 
solvents according to the following protocol: 
        
1. rotihistol   1 min 
2. xylene        1 min 
3. xylene:ethanol 5 min 
4. ethanol 96 % 5 min 
5. ethanol 75 % 5 min 
6. ethanol 50 % 5 min 
7.  H2O  5 min 
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4.2.7.1.2 Picrosirius red staining 
Picrosirius red (PSR) binds specifically to collagen fibers indicating the infarcted 
region where cardiomyocytes have been replaced by a collagenous scar. For PSR 
staining, rehydrated 7 µm paraffin tissue sections were stained in PSR solution for 20 
min. Sections were dehydrated, mounted in entellan and stored at room temperature.    
  
4.2.7.1.3 Ladewig staining 
The Ladewig trichrome staining provides insight into collagen fiber arrangement a 
histomorphological evaluation of parenchyma integrity and leukocyte infiltrate. 
Ladewig staining indicates collagen fibers in blue, nuclei in black and the cytoplasm 
in red and erythrocytes in orange. Staining was conducted using the Ladewig kit from 
Morphisto. Rehydrated 5 µm paraffin sections were stained for 3 minutes in the 
provided Weigert´s iron hematoxylin solution and subsequently washed for several 
times in tap water. Sections were incubated in phosphoric acid (1% w/ v) for 5 min, 
washed in desalted water and incubated in Ladewig staining solution for 3.30 min. 
After dehydration, slides were mounted with entellan and stored at room 
temperature.     
 
4.2.7.1.4 Alpha smooth muscle actin staining 
To assess myofibroblast numbers in the healing myocardium, alpha smooth muscle 
actin (α-SMA) was stained immunohistochemically using the Dako ARK™ peroxidase 
kit. On dehydrated sections, tissue-endogenous peroxidases were inactivated for 5 
min by incubation in peroxidase blocking reagent containing H2O2. The anti-α-SMA 
monoclonal antibody (clone 1A4, Dako) was biotinylated in antibody diluent for 15 
min and the antibody solution afterwards supplemented with the provided blocking 
reagent. Sections were incubated in presence of the antibody/ blocking reagent for 
15 min at a final antibody dilution of 1:50. After washing, sections were covered with 
the provided HRP-conjugated streptavidin solution for 15 min. For visualization, the 
chromogen 3,3'-diaminobenzidine (DAB, Abcam) was used according to the 
manufacturer´s protocol indicating α-SMA-positive cells after HRP-mediated DAB 
conversion into a brown chromophor. After washing, sections were stained with 
hematoxylin solution for 5 min, washed and mounted with entellan for light 
microscopy.  
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4.2.7.2 Immunofluorescence staining of Foxp3 
Immunofluorescence microscopy is characterized by visualization of cells or sub-
cellular components utilizing fluorophores. Frequently, protein labeling is achieved by 
fluorophore-conjugated antibodies directed against the target. After excitement with 
light of specific quality, fluorophores emit light in a defined wave length range. The 
usage of appropriate fluorophore and filter combinations allows the simultaneous 
visualization of different targets. The microscope, aperture, photo-multiplier and filters 
are operated from the computer.  
Tissue-Tek-covered samples were sliced into 5 µm sections using a cryo-microtome. 
Cryosections were fixed in 4% formaldehyde for 10 min and permeabilized in 0.5% 
dodecyltrimethylammonium with a 5 min PBS washing step in between. Sections 
were blocked in PBS containing 5% fetal calf serum for 30 min. After blocking, 
sections were covered with blocking buffer containing rat anti-mouse Foxp3 (clone 
FJK-16s) diluted 1:100 and incubated for 45 min. After two washing steps in PBS, an 
Alexa555-conjugated goat antibody directed against rat immunoglobulins diluted 
1:200 in PBS was added and sections incubated for 30 min. Additionally, Alexa488-
conjugated phalloidin was added (1:200) to stain filamentous actin. Nuclei were 
stained using DAPI. After washing, sections were mounted using Vectashield 
mounting medium (Vector laboratories). Samples were stored in the dark at 4°C. 
 
4.2.7.3 Image acquisition 
Bright-field images were acquired using an Axioskop 2 plus (Zeiss). For acquisition of 
immunofluorescence images, a Z1m Imager epifluorescence microscope (Zeiss) 
equipped with appropriate filter sets was employed.  
 
4.2.8 Infarct size determination 
To evaluate infarct size, PSR-stained cross-sections of the left ventricle were 
photographed at 25-fold magnification. Endocard and epicard length of the infarct 
zone were assessed using ImageJ software. The infarct size was calculated after 
assessment of both the entire left-ventricular endocard and epicard perimeter. 
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4.2.9 Evaluation of collagen content in the scar 
Collagen content was assessed by using circularly polarized light microscopy167. 
Collagen fibers have anisotropic properties and show birefringence under polarized 
light that is further enhanced by PSR. From each sample, one image was acquired 
using polarized light and a second image under bright-field illumination. The latter 
image was resolved into its cyan, yellow, magenta and black components using 
SigmaScan Pro. In the black-component image, collagen fibers appear dark gray/ 
black while non-collagen elements appear light gray/ white. In contrast, the image 
acquired by polarized light illumination shows collagen fibers as bright structures and 
non-collagen elements as dark structures. Digital subtraction of the “non-collagen” 
area in the black-component image from the polarized light image eliminates the area 
of interstitial and parenchymal space. The remaining image of “pure” collagen was 
kept for further analysis. The color of PSR-stained collagen fibers viewed with 
polarized light depends on fiber thickness. As fiber thickness increases, the color 
changes from green to yellow/ orange and red. In order to determine the collagenous 
area, the image depicting pure collagen was resolved into its hue (color), saturation 
and value. From the hue component, a histogram of hue frequency was obtained. 
Hue range smaller 129 was considered as collagen. The number of collagen pixels in 
the hue range was normalized to the total number of pixels in the image indicating 
the relative collagen area in the scar.  
 
4.2.10 Statistics 
Data are presented as mean value and SEM per group. For two group comparison, a 
Wilcoxon signed rank-sum test or, if suitable, an unpaired t test was conducted. For 
multiple comparisons, a one-way ANOVA was performed. Survival is shown as 
Kaplan-Meier curve analyzed by a log-rank test. Variance in a group was evaluated 
using the χ2 test. Group values were considered significantly different at P<0.05. 
Data analysis was performed using GraphPad Prism 4.03. 
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5 Results 
5.1 Both conventional and Foxp3+ regulatory CD4+ T lymphocytes 
become activated in response to MI 
To test whether CD4+ T cells become activated after MI, the expression of T cell 
activation markers was evaluated in infarcted and sham-operated mice. As T cell 
priming takes place in lymph nodes that drain the inflamed organ, heart-draining 
lymph nodes in the mediastinum were analyzed for CD4+ T cell proliferation. On day 
7 post-MI, the frequency of CD4+ T cells that expressed the proliferation marker Ki67 
was significantly increased as compared to sham-operated mice, indicating CD4+ T 
cell activation in lymph nodes after MI (Fig. 7A, B).  
 
 
 
 
 
 
To evaluate whether conventional or regulatory CD4+ T cells become activated after 
MI, both subsets were analyzed for the expression of the activation marker CD25. 
Compared to sham-operated mice, infarcted animals showed elevated frequencies of 
CD25-positive cells among conventional Foxp3-negative CD4+ T cells 3 days after MI 
(Fig.  8A, B), and absolute numbers of Foxp3-CD4+ T cells increased over time (Fig.  
8C). However, 56 days post-MI, the conventional CD4+ T cell compartment had 
contracted again to baseline levels (Fig.  8C).  
 
Fig. 7: CD4+ T cell proliferation after MI. Representative FACS plots (A) and the related 
analysis (B) showing the frequency CD4+ T cells expressing the proliferation marker Ki67 in 
heart-draining lymph nodes 7 days post-MI (n=4-5 per group, *P<0.05). 
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Similar to the activation of Foxp3-negative CD4+ cells, Foxp3+ Treg cells upregulated 
CD25 expression on a per-cell basis after MI as compared to sham-operated mice 
(Fig.  9A). The frequency of Foxp3+ cells among CD4+ T cells increased over time 
indicating that Treg cell proliferation overcame the expansion of conventional CD4+ T 
cells (Fig.  9B). Elevated frequencies of Foxp3+ cells persisted even after completion 
of healing and were still evident 56 days post-MI. In accordance with the observation 
that Treg cells become activated after MI, absolute Treg cell numbers escalated in 
heart-draining lymph nodes over time (Fig.  9C).  
Conclusively, both Foxp3-negative conventional and Foxp3+CD4+ regulatory T cells 
became activated after MI and expanded in heart-draining lymph nodes.  
 
 
Fig.  8: Activation and expansion of Foxp3-negative conventional T 
cells. A: Representative FACS plots showing CD25 expression on 
Foxp3-negative conventional cells. B: Frequencies of CD25-positive 
cells among conventional CD4 T cells (n=11-16 per group, * P<0.05). C: 
Absolute numbers of Foxp3-negative CD4+ T cells in heart-draining 
lymph nodes (n=5-7 per group, P<0.05). 
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5.2 CD4+ T Lymphocytes infiltrate the myocardium after MI 
Having observed that CD4+ T cells become activated after MI, T cell infiltration into 
the healing myocardium was evaluated. Compared to sham-operated animals, the 
proportion of Foxp3+ cells among CD4+ T cells, but also absolute Treg cell numbers in 
the infarct zone increased over time (Fig.  10A, B), whereas numbers of conventional 
CD4+ T cells escalated only by trend (Fig.  10C). As the FACS data indicated that Treg 
cell accumulated in the healing myocardium, their spatial distribution was evaluated 
using immunofluorescence microscopy. In line with the FACS analysis, Foxp3-
positive cells could be found in the infarct zone (Fig.  10D). Moreover, Foxp3+ cells 
were detected in both the infarct border and the non-injured remote myocardium, i.e. 
still functional parenchyma that was not subjected to ischemia (Fig.  10D).  
 
Fig.  9: Activation and expansion of Treg cells in heart-draining lymph nodes.  
A: Representative FACS plots and analysis of CD25 expression on Treg cells (right, n=3-4, 
*P<0.05). B: Frequency of Foxp3+ cells among CD4+ T cells (n=4-7 per group, *P<0.05 vs. 
sham d7). C: Absolute Treg cell numbers (n=4-6 per group, *P<0.05). (Weirather et al., 
Circulation Research, 2014168) 
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5.3 Survival and wound healing are impaired in MHC class II-deficient 
mice 
In order to reveal the functional role of CD4+ T cells for wound healing post-MI, 
permanent coronary artery ligation was induced in MHC class II-deficient mice that 
lack MHCII-restricted αβ CD4+ T cells. In comparison to WT mice, MHCII KO mice 
showed a significantly impaired survival due to a higher incidence of left-ventricular 
ruptures (WT: 79% vs. MHCII KO 52%, Fig.  11A). However, infarct size, left-
Fig.  10: CD4+ T cells in hearts of sham-operated or the healing myocardium of 
infarcted mice. A: Frequency of Foxp3+ cells among CD4+ T cells. B: Absolute Treg cell 
numbers in the heart (n=3-8 per group, *P<0.05). C: Absolute numbers of conventional 
CD4+ T cells in the heart (n=6-9 per group, *P<0.05). D: Immunofluorescence microscopy 
of Foxp3-positive cells in the infarct core, the infarct border and the remote myocardium 
adjacent to the infarct zone. Foxp3-positive cells are depicted in purpble (arrow heads). 
Phalloidin-positive surviving cardiomyocytes are shown in green. Nuclei were stained 
using DAPI (blue). Images were acquired at 400-fold magnification. (Weirather et al., 
Circulation Research, 2014168)    
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ventricular remodeling or fractional shortening were not significantly different 
between genotypes (Fig.  11B, C, D). 
 
 
 
The prevalence of infarct ruptures in MHCII KO mice spurred an evaluation of the 
scar tissue integrity. Compared to WT mice, MHCII KO littermates showed a reduced 
collagen density and disarrayed collagen fiber deposition in the infarct zone on day 7 
post-MI as evaluated by Ladewig staining (Fig.  12A). Collagen density in the infarct 
zone was assessed by polarized light microscopy of Picrosirius Red (PSR)-stained 
LV cross-sections. As compared to WT littermates, less collagen per unit area was 
found in MHCII KO mice, indicating that scarring was disturbed these animals (Fig.  
12B, C).  
 
Fig.  11: Clinical outcome of wildtype (WT) and MHCII KO mice after MI. A: Cumulative 
survival of infarcted mice (n=19-21 per group, *P<0.05). B: Infarct size 7 days after MI. C, D: 
Echocardiographic evaluation of end-diastolic area (EDA) and fractional shortening (FS) in 
infarcted mice 7 days after MI. (Hofmann, Beyersdorf, Weirather et al., Circulation, 2012169) 
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In summary, compared to WT animals, MHCII KO mice were characterized by an 
increased mortality due to a disturbed scar tissue formation that resulted in a higher 
prevalence of left-ventricular ruptures.  
5.4 Survival and wound healing are impaired in OT-II mice 
To address whether the mere absence or functional deficits of CD4+ T cells were 
responsible for the fatal clinical outcome of MHCII KO mice, MI was induced in OT-II 
mice. In these animals, most CD4+ T cells bear a transgenic TCR specific for an 
ovalbumin-derived peptide presented in the context of MHC class II. As the TCR 
repertoire in the CD4+ T cell compartment is highly limited in OT-II mice, the vast 
majority of CD4+ T cells cannot recognize self-peptides such as auto-antigens 
released during myocardial injury. Compared to WT animals, OT-II mice showed, 
similar to MHCII KO mice, a significantly impaired survival due to a prevalence of left-
ventricular ruptures. By day 56, survival was 77% in WT and 49% in OT-II mice (Fig.  
Fig.  12: Scar tissue formation in infarcted wildtype and MHCII KO mice. A: 
Representative images showing the infarct core 7 days post-MI after Ladewig staining. 
Collagen fibers are stained blue, nuclei black, erythrocytes orange and cytoplasm red. 
Images are shown at 400-fold magnification. B: Representative images showing PSR-
stained collagen (red) by polarized light microscopy. Images were acquired at 200-fold 
magnification C: Normalized proportion of the collagen amount in the infarct zone of 
wildtype (WT) and MHCII KO mice (n=3-4 per group, *P<0.05). (Hofmann, Beyersdorf, 
Weirather et al., Circulation, 2014169) 
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13A). Regarding infarct size, left-ventricular remodeling or fractional shortening, no 
differences were found between genotypes (Fig.  13B, C, D). As OT-II mice 
deceased primarily due to left-ventricular ruptures in the first 7 days post-MI, scar 
tissue formation was assessed. Similar to MHCII-deficient animals, Ladewig staining 
revealed a decreased collagen density and disarrayed collagen fiber alignment in the 
infarct zone of OT-II mice as compared to WT animals (Fig.  13E).  
 
 
 
 
In summary, the clinical postinfarction phenotype of OT-II mice closely resembled the 
phenotype of MHCII KO mice characterized by impaired survival and disturbed scar 
Fig.  13: Clinical outcome of wildtype (WT) and OT-II mice. A:  Cumulative survival after MI 
or sham surgery (n=39-44, *P<0.05). B: Infarct size 7 days after MI. C, D: End-diastolic area 
(EDA) and fractional shortening (FS) 7 days after MI. E: Representative images showing the 
infarct core 7 days post-MI after Ladewig staining. Collagen fibers are stained blue, nuclei 
black and cytoplasm red. Images are shown at 400-fold magnification. (Hofmann, Beyersdorf, 
Weirather et al., Circulation, 2012169) 
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tissue formation that ultimately led to a higher incidence of left-ventricular ruptures. 
The data indicates that antigen recognition by CD4+ T cells constitutes an 
indispensable prerequisite for proper and organized infarct healing.  
5.5 Activation of conventional and regulatory CD4+ T cells in response 
to MI depends on antigen recognition 
Having observed that antigen recognition by CD4+ T cells is crucial for wound healing 
post-MI, activation and expansion of both conventional and regulatory T cells was 
studied in heart-draining lymph nodes. On day 3 after MI induction, WT animals 
showed, compared to sham-operated WT mice, increased frequencies of CD25-
positive cells among Foxp3-negative conventional CD4+ T cells indicating T cell 
activation in these mice (Fig.  14A, B). In contrast, CD4+ conventional T cells in 
infarcted OT-II mice did not show upregulated CD25 levels as compared to sham-
operated OT-II animals (Fig.  14A, B). Similarly, Foxp3+ Treg cell frequencies were 
elevated in infarcted WT mice in comparison to sham-operated WT controls, but not 
in infarcted OT-II mice as compared to OT-II sham controls (Fig.  14A, C). 
Consistently, on day 7 post-MI, both absolute numbers of conventional and 
regulatory T cells were increased in heart-draining lymph nodes of wildtype mice, but 
not in TCR transgenic OT-II mice (Fig.  14D).  
Collectively, the activation of both conventional and regulatory CD4+ T cells after MI 
is strictly antigen-dependent and requires antigen recognition via the TCR.  
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5.6 Specific diphtheria toxin-induced Treg cell ablation in DEREG mice 
leads to increased infarct size and deteriorated cardiac function.  
The observation that CD4+ T cell crucially influence healing and clinical outcome after 
MI raised the question for the mechanistic link between CD4+ T cell activation and 
scar tissue construction as well as cardiac inflammation. Hypothesizing that anti-
inflammatory Treg cells, but not conventional T cells facilitate wound healing after MI 
spurred additional experiments focusing on the functional relevance of Treg cells in 
postinfarction healing and remodeling.  
Fig.  14: Activation and expansion of conventional CD4+ T cells and Foxp3+CD4+ 
T cells in heart-draining lymph nodes of wildtype (WT) and OT-II mice 7 days 
after MI. A: Representative FACS plots showing CD25 expression on conventional 
Foxp3-CD4+ cells and Foxp3+CD4+ cells. B:  Evaluation of CD25 upregulation on 
Foxp3-CD4+ T cells (#P<0.05 vs. WT MI, *P<0.05 vs. sham MI). C: Analysis of Foxp3+ 
frequencies among CD4+ cells (#P<0.05 vs. WT MI, *P<0.05 vs. sham MI). D: Ratio 
of CD4+ T cell numbers to CD4+ T cell numbers in sham-operated mice. Left: Fold-
change of Foxp3-negative conventional CD4+ T cells. Right: Fold-change of 
Foxp3+CD4+ Treg cells (*P<0.05). (Hofmann, Beyersdorf, Weirather et al., Circulation, 
2012169)   
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To test whether Treg cells influence healing and clinical outcome after MI, the Treg cell 
compartment was specifically ablated by diphtheria toxin (DTX) administration to 
DEREG mice in which Foxp3+ cells transgenically express the human DTX receptor. 
Treg cells were depleted 2 days prior to MI induction. To prevent a Treg cell rebound 
from the bone marrow, DTX was additionally injected on day 2 and day 4 after 
surgery. In comparison to DTX-treated wildtype littermates, DEREG mice exhibited 
an efficient depletion of Foxp3+ cells from the peripheral blood and the heart-draining 
lymph nodes at the time point of MI induction (Fig. 15). Moreover, accumulation of 
Treg cells in the healing myocardium was prevented in DEREG mice (Fig. 15).   
 
  
 
 
 
 
 
Treg cell depletion had no impact on the cumulative survival (Fig.  16A). However, 
DTX-treated DEREG mice showed significantly larger infarcts as compared to DTX-
treated wildtype littermates (Fig.  16B). Furthermore, lung weight to body weight 
ratios were increased in Treg cell-deficient mice indicating pulmonary edema due to 
impaired cardiac output (Fig.  16C). To evaluate whether Treg cell ablation would 
influence remodeling and cardiac function, non-invasive echocardiography was 
performed at baseline, on day 3 and on day 7 post-MI. At baseline, no differences in 
echocardiographic parameters were found between the groups (data now shown). 
Fig. 15: Evaluation of Treg cell depletion in DEREG mice. 
Representative FACS plots and quantitative analyses showing the 
frequency of Foxp3+ cells among CD4+ T cells in blood, 
mediastinal lymph nodes and the healing myocardium of 
diphtheria toxin-treated wildtype and DEREG mice. (Weirather et 
al., Circulation Research, 2014168) 
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However, compared to Treg cell-sufficient mice, Treg cell-depleted animals exhibited a 
tendency towards an increased left-ventricular dilatation on day 7 post-MI (Fig.  16D). 
Moreover, apical fractional shortening was significantly impaired on day 3 and, by 
trend, on day 7 post-MI, indicating deteriorated LV contractile function in Treg cell-
deficient mice (Fig.  16E).  
 
  
 
To evaluate if disturbed scar tissue formation was responsible for the observed 
cardiac deterioration in DEREG mice, the expression of pro-collagens as well as 
collagenolytic enzymes was assessed. Compared to DTX-treated WT mice, Treg cell-
depleted DEREG mice did not show differences regarding pro-collagen alpha 1 (III) 
Fig.  16: Clinical outcome of Treg cell-sufficient wildtype (WT) and Treg 
cell-ablated DEREG mice after MI. A, B: Survival (n=14-17) and infarct 
size 7 days post-MI (n=8-11, *P<0.05). C: Apical end-diastolic area (EDA) 
on day 7 after MI (n=8-11 per group, *P<0.05). D: Percentage of apical 
fractional shortening (FS) on day 3 and day 7 (n=8-11 per group, 
*P<0.05). E: Lung weight to body weight ratios (n=8-11 per group, 
*P<0.05). (Weirather et al., Circulation Research, 2014168) 
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and pro-collagen alpha 1(I) expression that predominantly contribute to the early 
postinfarction scar tissue construction (Fig.  17A). Matrix metalloproteinases (MMPs) 
catalyse the collagen turnover in the healing myocardium. As MMP-2 and MMP-9 
have been demonstrated to critically influence LV remodeling, the expression of both 
enzymes was assessed. At the mRNA level, however, no differences regarding 
MMP-2 and MMP-9 mRNA synthesis were found between the groups (Fig.  17B). In 
vivo, MMPs are tightly regulated by tissue inhibitors of matrix metalloproteinases 
(TIMPs). As net MMP activity depends on the MMP : TIMP ratio, mRNA expression 
of MMP-2-regulating TIMP-2 and MMP-9-restraining TIMP-1 were additionally 
evaluated. Five days after MI, no differences regarding TIMP-1 and TIMP-2 
expression were identified between groups (Fig.  17C). 
 
  
 
 
 
 
 
Fig.  17: Real-time RT-PCR analysis of scar-constructing 
collagens, collagenolytic enzymes and related inhibitors 
in DEREG and WT mice 5 days after MI. A: mRNA 
expression of pro-collagens alpha 1 (III) (Col3a1) and alpha 
1 (I) (Col1a1) (n=4 per group). B: Real-time RT-PCR 
analysis of matrix metalloproteinase 2 (MMP-2) and MMP-9 
(n=4 per group). C: tissue inhibitor of matrix 
metalloproteinase 1 (TIMP-1) and TIMP-2 (n=4 per group). 
(Weirather et al., Circulation Research, 2014168) 
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Collectively, Treg cell ablation prior to MI leads to an increased infarct size and 
deteriorated cardiac function.  
5.7 Treg cell ablation in DEREG mice leads to an accumulation of both 
inflammatory myeloid and T cells in the infarct zone 
To elucidate the mechanism why Treg cell-deficient mice exhibit a deteriorated cardiac 
function, the influx and polarization of both myeloid cells and T cells were evaluated. 
In comparison to DTX-treated WT mice, absolute numbers of CD11b+Ly-6G+ 
neutrophils were increased in the healing infarct of Treg cell-depleted DEREG mice 
(Fig.  18A). Furthermore, the composition of the monocyte compartment was shifted 
towards the inflammatory Ly-6Chigh subset (Fig.  18B).  
 
 
 
 
 
 
 
 
 
Fig.  18: Neutrophil numbers and monocyte subset 
composition in the infarct zone of Treg cell-sufficient 
and Treg cell-depleted mice 7 days after MI. A: 
Representative FACS histogram showing the proportion 
of Ly-6G+ neutrophils among leukocytes and absolute 
neutrophil numbers per mg scar tissue (n=3-6 per group, 
*P<0.05). B: Representative FACS plot (left) and 
analysis (right) depicting the frequency of Ly-6Chigh 
monocytes among CD11b+Ly-6G- monocytes/ 
macrophages (n=3-5 per group, *P<0.05). (Weirather et 
al., Circulation Research, 2014168) 
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As macrophages pivotally modulate postinfarction healing, monocyte/ macrophage 
polarization in the infarct zone was evaluated. To address this question, 
CD45+CD11b+Ly-6G- monocytic cells were sorted from the healing myocardium 5 
days post-MI. After RNA amplification, cDNA was synthesized and expression levels 
of classic M1 and M2 mediators evaluated (Fig.  19). 
 
  
 
 
 
 
 
 
 
 
Monocytes sorted from the infarct of Treg cell-ablated mice showed an increased 
expression of M1-associated iNOS, but no difference with respect to TNFα mRNA 
synthesis (Fig. 20A). To evaluate whether the observed M1 bias in sorted monocytic 
cells correlated with an attenuated M2 polarization, the expression of typical M2-
associated mediators involved in healing was assessed. Compared to DTX-treated 
WT littermates, DEREG mice exhibited an elevated mRNA synthesis of inflammation-
resolving IL-10 and TGFβ1 (Fig. 20B). Furthermore, Treg cell depletion was 
associated with downregulated mRNA synthesis of wound-stabilizing osteopontin 
(OPN) and, by trend, transglutaminase factor XIII (FXIII) in the sorted monocyte/ 
macrophage population (Fig. 20C).     
Fig.  19: Workflow to evaluate monocyte/ 
macrophage polarization in the healing 
myocardium. CD11b+Ly-6G+ monocytic cells were 
sorted from the infarct 5 days post-MI. After RNA 
amplification and cDNA synthesis, expression of 
prototypical M1 or M2 markers/ mediators was 
assessed by Real-time RT-PCR. 
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As T cells are capable of secreting soluble mediators that modulate macrophage 
polarization, T cell infiltration into the healing infarct was assessed. Treg cell-depleted 
mice showed heightened numbers of both CD4+ and CD8+ T cells in the infarct zone 
as compared to wildtype mice 5 days after MI. (Fig.  21A, B). As IFNγ and TNFα 
represent classic T cell-derived cytokines with capacity to induce M1 cells, the 
synthesis of both cytokines in the bulk scar tissue was assessed on day 5 post-MI. In 
accordance with the M1 macrophage polarization in Treg cell-ablated mice, both IFNγ 
and TNFα mRNA expression were significantly increased in these hearts as 
compared to WT littermates (Fig.  21C). 
 
Fig. 20: Real-time RT-PCR analysis of M1- and M2-associated 
mediators in monocytes/ macrophages sorted from the scar 
of DTX-treated DEREG and wildtype (WT) mice 5 days after 
MI. A: mRNA expression of M1-associated induced NO synthase 
(iNOS) and TNFα (n=5 per group, *P<0.05). B, C: mRNA levels of 
M2-associated interleukin-10 (IL-10), TGFβ1 (transforming growth 
factor beta), osteopontin (OPN) and factor XIII (FXIII) (n=5 per 
group, *P<0.05). (Weirather et al. Circulation Research, 2014168) 
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Fig.  21: T cell influx and expression of classic M1-inducing T cell mediators in Treg cell-ablated 
and Treg cell-sufficient mice. A, B:  Representative FACS plots and absolute T cell numbers of both 
CD4+ (A) and CD8+ (B) T cells in the healing myocardium 5 days post-MI (n=3 per group, *P<0.05). C: 
mRNA expression of IFNγ and TNFα in the bulk scar 5 days after MI (n=5 per group, *P<0.05). 
(Weirather et al., Circulation Research, 2014168) 
 
 
To evaluate whether T cells are indeed capable of producing IFNγ and TNFα in 
infarcted mice, lymphocytes from heart-draining lymph nodes were analyzed for 
TNFα and IFNγ production by intracellular cytokine staining. In comparison to WT 
littermates, both CD4+ and CD8+ T cells showed elevated frequencies of IFNγ-
expressing cells in DTX-treated DEREG mice (Fig.  22A, B). Furthermore, the 
proportion of TNFα-positive cells was elevated in CD8+ T cells in lymph nodes from 
these mice in contrast to CD4+ T cells that did not show increased frequencies of 
TNF-expressing cells after Treg cell ablation (Fig.  22C). However, TNFα mean 
fluorescence intensity (MFI) of TNFα-positive CD4+ cells was higher in Treg cell-
depleted animals indicating augmented synthesis on a per cell basis (Fig.  22D).  
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Fig.  22: Cytokine production in both CD4+ and CD8+ T cells in heart-draining lymph nodes of 
DTX-treated DEREG and wildtype mice 5 days post-MI. A: Representative FACS plots showing 
IFNγ- and TNFα-positive T cells (n=3 per group, *P<0.05). B: Frequency of IFNγ-positive T cells. C: 
Proportion of TNFα-positive T cells (n=3 per group, *P<0.05). D: Mean fluorescence intensity (MFI) of 
TNFα staining in TNFα-positive CD4+ T cells (n=3 per group, *P<0.05). (Weirather et al., Circulation 
Research, 2014168) 
 
In summary, Treg cell depletion prior to MI induction provokes an increased 
recruitment of inflammatory myeloid and T cells into the infarct zone, in line with an 
M1-like macrophage polarization that is presumably driven by T cell-derived IFNγ 
and TNFα.  
5.8 Anti-CD25 antibody-mediated Treg cell depletion prior to MI leads to 
impaired survival, aggravated remodeling and increased recruitment 
of inflammatory myeloid cells. 
To reconfirm the results of cardiac exacerbation in Treg cell-ablated mice, a second 
model of Treg cell depletion was employed, i.e. an anti-CD25 antibody (Ig)-mediated 
ablation. Compared to the control mice that received an isotype control antibody of 
irrelevant specificity, anti-CD25 antibody administration resulted in a significant 
reduction of Foxp3+ frequencies among CD4+ T cells in the blood and mediastinal 
lymph nodes (Fig.  23). 
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Anti-CD25 antibody treatment resulted in significantly impaired survival as compared 
to the control group (Fig.  24A). Infarct size was not different between treatment 
groups evaluated 7 days after MI (Fig.  24B). However, echocardiography revealed 
an aggravated left-ventricular apical end-diastolic area implying that Treg cell-depleted 
mice had likely succumbed to heart failure (Fig.  24C). Regarding fractional 
shortening and the incidence of left-ventricular ruptures, however, no differences 
were found between the treatment groups (Fig.  24C, D and data not shown).  
 
Fig.  23: Evaluation of Treg cell depletion in 
antibody-treated mice. Representative FACS plots 
and quantitative analyses showing the frequency of 
Foxp3+ cells among CD4+ T cells in blood and 
mediastinal lymph nodes after anti-CD25 antibody or 
isotype control antibody (Ig) treatment (n=3 per 
group; *P<0.05). (Weirather et al., Circulation 
Research, 2014168) 
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Similarly to DTX-treated DEREG mice, anti-CD25 antibody administration enhanced 
the influx of inflammatory myeloid cells into the healing infarct zone. Absolute 
neutrophil numbers as well as the proportion of Ly-6Chigh monocytes were heightened 
in hearts of anti-CD25 antibody-treated animals in comparison to control mice (Fig.  
25).  
 
 
 
 
 
In summary, anti-CD25 antibody-mediated Treg cell depletion aggravated 
postinfarction clinical outcome characterized by impaired survival and deteriorated 
left-ventricular dilatation.  
Fig.  24: Clinical outcome of anti-CD25 antibody- and isotype control antibody (Ig)-
treated mice. A: Cumulative survival of treated mice (n=16-34 per group at baseline, 
*P<0.05). B: infarct size evaluated 7 days after MI (n=4-7 per group, *P<0.05). C, D: apical 
end-diastolic area (EDA) and apical fractional shortening in treated mice 7 days after MI (n= 
4-7 per group, *P<0.05). (Weirather et al., Circulation Research, 2014168) 
Fig.  25: Composition of myeloid cells in the infarct zone of 
treated mice 7 days after MI assessed by FACS analysis.  
A: Absolute number of neutrophils (n=3-7 per group; *P<0.05). 
B: Proportion of Ly-6Chigh cells among monocytes (n=3-7 per 
group; *P<0.05) (Weirather et al, Circulation Research, 2014168) 
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5.9 CD28-SA administration leads to enhanced Treg cell recruitment into 
the infarct zone, associated with increased survival and improved 
scar tissue formation  
The observation that Treg cell depletion prior to MI exacerbated clinical outcome 
raised the hypothesis that an activation and expansion of the Treg cell compartment 
might improve healing and alleviate adverse cardiac remodeling. Treg cell activation 
was accomplished by a single injection of a superagonistic anti-CD28 monoclonal 
antibody (CD28-SA). CD28-SA-mediated Treg cell expansion peaks approximately 2-
3 days after administration163, 170. To support the physiological Treg cell expansion that 
was found to reach its maximum between day 3 and day 7 after MI, the CD28-SA 
was administered 2 days after surgery. By day 5, the frequency of Foxp3+ cells 
among CD4+ T cells in both blood and heart-draining lymph nodes was 
approximately doubled after CD28-SA injection as compared to control antibody-
treated mice (Fig.  26). 
  
 
 
 
 
 
Compared to isotype control Ig-treated mice, CD28-SA administration resulted in 
improved survival and significantly reduced frequencies of left-ventricular ruptures. 
By day 56, survival was 47.1% in isotype controls and 76.6% in CD28-SA-treated 
animals (Fig.  27A). Frequencies of left-ventricular ruptures were 23% in control mice 
Fig.  26: Treg cell expansion in CD28-SA-
treated mice. Representative FACS plots and 
quantitative analyses showing the frequency of 
Foxp3+ cells among CD4+ T cells in blood and 
mediastinal lymph nodes (mLN) after injection 
of CD28-SA or an isotype control Ig (n=3 per 
group; *P<0.05). (Weirather et al., Circulation 
Research, 2014168) 
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and 5% after CD28-SA treatment (Fig.  27B). Regarding infarct size, left-ventricular 
dilatation and fractional shortening, however, no significant differences could be 
found between the treatment groups evaluated by non-invasive echocardiography 7 
days after MI (Fig.  27D, E).  
 
 
 
The fact that therapeutic CD28-SA administration resulted in decreased rates of left-
ventricular ruptures suggested that scar tissue formation was improved or 
accelerated in these mice in comparison to controls. Therefore, the quality of scar 
tissue formation was analyzed in both treatment groups. Collagen I and collagen III 
constitute integral components of the reparative scar. In comparison to control mice, 
CD28-SA administration led to increased mRNA expression of pro-collagen alpha-1 
(I) and pro-collagen alpha-1 (III) in the emerging scar 5 days after MI (Fig.  28A). The 
increased expression of collagen I and collagen III in CD28-SA-treated mice was 
confirmed at the protein level (Fig.  28B). ECM turnover in the infarct zone is, among 
other enzymes, driven by MMPs. As both MMP-2 and MMP-9 activity in postinfarction 
healing have been correlated with left-ventricular ruptures, the expression of MMP-2- 
and MMP-9-restraining TIMPs was assessed. Compared to isotype control antibody-
Fig.  27: Clinical outcome of CD28-SA- and istoype control antibody (Ig)-treated 
mice. A: Cumulative survival after MI (n=42-47 per group at baseline, *P<0.05). B: 
frequency of left-ventricular ruptures during the first 7 days post-MI (B, n=45-62, 
*P<0.05). C: Infarct size assessed on day 7 after MI. D: Apical end-diastolic area (EDA) 
and fractional shortening (FS) 7 days post-MI. (Weirather et al., Circulation Research, 
2014168) 
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treated mice, CD28-SA treatment resulted in elevated TIMP-1 as well as TIMP-2 
synthesis in the healing infarct 5 days after MI (Fig.  28C).  
 
 
 
 
 
 
 
 
 
Collagen deposition in the healing infarct is carried out by mesenchymal alpha 
smooth muscle actin (α-SMA)-expressing myofibroblasts. As an indirect readout for 
myofibroblast numbers in the infarct scar, the expression level of both α-SMA and the 
mesenchymal marker vimentin were evaluated. Compared to control mice, vimentin 
and α-SMA mRNA expression were significantly upregulated after CD28-SA-
treatment on day 5 after MI (Fig.  29A). 
As α-SMA can be expressed in endothelial cells, neo-vessel numbers were indirectly 
assessed by an evaluation of von Willebrandt factor (vWF) expression reflecting the 
Fig.  28: Scar tissue construction after CD28-SA or isotype 
control antibody (Ig) administration evaluated on day 5 post-MI. 
A: mRNA expression of collagen alpha 1 (I) (Col1a1) and collagen 
alpha 1 (III) (Col3a1) (n=4-7 per group per group, *P<0.05). B: 
Western blot analysis of both collagen I, collagen III and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). C: Real-time 
RT-PCR analysis of tissue inhibitor of matrix metalloproteinase 1 
(TIMP-1) and TIMP-2 in bulk scar tissue homogenates (n=4-7, 
*P<0.05). (Weirather et al., Circulation Research, 2014168) 
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degree of tissue neovascularization. As compared to isotype control antibody-treated 
mice, CD28-SA injection did not elicit vWF mRNA upregulation implying that elevated 
α-SMA mRNA synthesis was not secondary to an accelerated angiogenesis (Fig.  
29B). Heightened numbers of α-SMA-expressing cells could be confirmed by 
immunohistochemistry stainings (Fig.  29C).    
 
 
 
In order to unravel whether Treg cells influence cardiac healing directly in the heart, 
Treg cell influx into the infarct zone was assessed. CD28-SA-treated animals showed 
similar frequencies of bulk CD4+ T cells among CD45+ leukocytes present on day 5 
after MI as compared to control mice (Fig.  30A). However, the proportion of Foxp3+ 
bona fide regulatory T cells among CD4+ T cells was shifted after CD28-SA treatment 
showing approximately 50% Foxp3+ cells among CD4+ T cells as compared to 
approximately 25% Foxp3+ cells among heart CD4+ cells of isotype control antibody-
treated mice (Fig.  30B, C). Consistently, absolute numbers of Foxp3+CD4+ 
regulatory cells were elevated in the healing infarct of CD28-SA-treated animals (Fig.  
30D) and heightened Treg cell numbers could be further reconfirmed by 
Fig.  29: Evaluation of myofibroblast numbers in the infarct zone of treated mice. 
A: mRNA synthesis of mesenchymal vimentin and alpha smooth muscle actin (α-SMA) 
in scar tissue homogenates 5 days after MI (n=4-7 per group; *P<0.05). B: Real-time 
RT-PCR analysis of von Willebrandt factor (vWF) 5 days after MI (n=4-7 per group; 
*P<0.05). C: Immunohistochemistry staining of a-SMA 7 days after MI (brown: α-SMA-
positive cells exemplarily indicated by arrow head, blue: cell nuclei, bar represents 50 
µm). (Weirather et al., Circulation Research, 2014168) 
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immunofluorescence stainings (Fig.  30E). To assess whether CD28-SA treatment 
alone imposed heart-seeking capacity on the Treg cell compartment irrespective of 
cardiac injury, Treg cell influx into the heart of treated mice was assessed after sham 
surgery. However, CD28-SA administration in absence of MI did not elicit 
pronounced recruitment of Treg cells into the myocardium, indicating that tissue 
inflammation during sterile injury in terms of MI constitutes a prerequisite for Treg cell 
homing into the heart (Fig.  30F). 
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Fig.  30: CD4+ T cell infiltrate in the scar tissue of CD28-SA and isotype 
control antibody (Ig)-treated mice 5 days after MI (A-E) or sham surgery 
(F). A: Representative FACS plots showing CD4+ T cell frequencies among 
CD45+ leukocytes in the scar tissue. Numbers indicate percentage among all 
CD45+ leukocytes. B: Representative histograms depicting Foxp3+ cells among 
CD4+ T cells. C: Proportion of Foxp3+ cells among CD4+ T cells in the scar 
tissue (n=4-5 per group; *P<0.05). D: Absolute numbers of Foxp3+CD4+ Treg 
cells in the scar tissue of treated animals (n=4-5 per group; *P<0.05). E: 
Immunofluorescence staining of Foxp3+ cells in the scar tissue 5 days after MI. 
Foxp3 is depicted in purple (arrow heads). Nuclei were stained using DAPI. The 
scale bar indicates 100 µm. F: Representative FACS plots showing frequencies 
of Foxp3-positive cells among cardiac CD4+ T cells 5 days post-surgery after 
administration of an isotype control antibody or CD28-SA to sham-operated 
mice. (Weirather et al., Circulation Research, 2014168) 
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In summary, therapeutic Treg cell activation 2 days after MI led to increased Treg cell 
recruitment into the healing myocardium, associated with increased de novo collagen 
synthesis and, consistently, improved survival due to reduced frequencies of left-
ventricular ruptures. 
5.10  Therapeutic Treg cell activation induces an M2-like macrophage 
polarization in the healing myocardium 
Since monocytic cells are key players for cardiac wound healing after MI, the 
absolute number of monocytes/ macrophages within the scar tissue was assessed 
on day 7 after MI induction. Regarding absolute cell numbers and monocyte subset 
composition, no difference could be detected between treatment groups (data not 
shown). However, as monocytic cells exhibit high functional plasticiy, the polarization 
state of monocytes/ macrophages in the healing myocardium was assessed. In the 
first place, the expression of mediators with capacity to induce healing-promoting M2 
cells was determined. In comparison to isotype control Ig-treated mice, mRNA levels 
of transforming growth factor beta 1 (TGFβ1), interleukin-13 (IL-13) and interleukin-
10 (IL-10) were significantly upregulated in the scar tissue of CD28-SA-treated mice 
on day 5 after MI (Fig.  31A). The increased expression of M2-associated arginase I 
and CD206 in line with ECM-bracing osteopontin (OPN) and factor XIII (FXIII) 
indicate that M2 cells were, indeed, present in these hearts (Fig.  31B). 
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To verify that monocytic cells account for the upregulation of M2 markers in the 
healing myocardium of CD28-SA-treated mice, CD11b+Ly-6G- monocytes/ 
macrophages were sorted from the scar tissue 7 days after MI and, subsequently, 
analyzed for M1- and M2-prototypic markers (see Fig.  19). In comparison to 
controls, monocytes/ macrophages sorted from the scar of CD28-SA-treated mice 
showed elevated mRNA levels of the M2-associated markers ariginase I, CD206, 
TGFβ1 and IL-10 in line with a reduced synthesis of M1-associated TNFα message 
(Fig.  32A, B). However, regarding the expression of the M1 mediators IL-1β and IL-
6, no significant differences were identifiable between treatment groups (Fig.  32B).   
 
Fig.  31: Expression of M2-associated mediators in scar tissue homogenates in treated 
mice 5 days after MI. A: mRNA synthesis of M2-inducing IL-13, IL-10 and TGFβ1. B: Real-
time RT-PCR analysis of M2-associated arginase I, CD206, osteopontin (OPN) and 
transglutaminase factor XIII (FXIII) (n=4-7 per group, *P<0.05). (Weirather et al., Circulation 
Research, 2014168) 
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Conclusively, therapeutic Treg cell activation led to an upregulation of M2-inducing 
factors in the healing myocardium, correlating with a pronounced M2 transcriptional 
profile in scar macrophages characterized by an expression of inflammation-
resolving and healing-promoting factors.  
5.11  Treg cell-derived cytokines drive M2 polarization in monocytic cells 
in vitro 
In the healing myocardium of CD28-SA-treated mice, Treg cell numbers were 
significantly elevated as compared to controls, suggesting that Treg cells might 
influence macrophage polarization in situ. To investigate the potential impact of 
CD28-SA-activated Treg cells on monocyte/ macrophage differentiation in vivo, 
primary monocytic cells and T cell subsets were cultured in vitro in different 
combinations (Fig.  33).  
 
Fig.  32: Monocytes/ macrophages sorted from the healing infarct 7 days after MI. 
Real-time RT-PCR analysis of M2-associated arginase I, TGFβ1 and IL-10 (A) as well as 
M1-associated TNFα, IL-1β and IL-6 (B) (n=3-4 per group, *P<0.05). (Weirather et al., 
Circulation Research, 2014168) 
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Fig.  33: Experimental setup to evaluate the impact of CD28-SA-activated Treg cells and 
conventional T cells on monocyte/ macrophage differentiation in vitro. Primary monocytes, Treg 
cells and conventional T cells (T) were cultivated alone or in different combinations in presence of IL-2 
and CD28-SA or an isotype control antibody (Ig) of irrelevant specificity. The antibodies were coated 
on polymer beads before addition to the cell culture. After 4 days of incubation, cell culture 
supernatants were analyzed for the M2 macrophage-associated mediator osteopontin.    
 
 
Monocytes/ macrophages were sorted from lymph nodes as well as the spleen and 
defined as CD45+CD11bhighLy-6G-CD11c-. Conventional and regulatory CD4+ T cells 
were sorted from peripheral lymph nodes and defined as CD45+CD4+CD25- and 
CD45+CD4+CD25high, respectively (Fig.  34).  
 
 
Fig.  34: Sorting strategy to purify primary monocytes/ macrophages (A), 
conventional CD4+ T cells and regulatory CD4+ T cells (B). A: Monocytic cells were 
defined as CD45+CD11b+Ly-6G-CD11c- and sorted from T and B cell-deprived cell 
suspensions prepared from spleen and lymph nodes. B: Conventional and regulatory CD4+ 
T cells were sorted from lymph node single cell suspensions and defined as CD4+CD25- 
and CD4+CD25high, respectively. (Weirather et al., Circulation Research, 2014168)  
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Post-sort purity of T cell subsets was analyzed on the basis of Foxp3 expression. 
After 4 days of incubation in presence of IL-2 and either CD28-SA or an isotype 
control antibody, T cell activation was assessed by an expression analysis of Ki67 
that is strictly associated with cellular division (Fig.  35).  
 
 
 
As OPN represents a prototypical M2 mediator that is crucially involved in 
postinfarction healing, macrophage M2 polarization was evaluated on the basis of 
OPN synthesis. Mono-cultures of Treg cells, conventional CD4+ T cells and monocytic 
cells showed minor OPN concentrations in the supernatant after 4 days of incubation 
in presence of CD28-SA and IL-2 (Fig.  36A). In contrast, co-cultures of Treg cells and 
monocytic cells showed high OPN secretion after CD28-SA and IL-2 stimulation, but 
not in presence of IL-2 and an isotype control antibody (Fig.  36A).  
Treg cell numbers of 150 cells per mg scar tissue in the infarcted myocardium are 
considerably low as compared to the predominant fraction of approximately 2000 
macrophages per mg tissue136. To evaluate whether the unpropitious Treg cell : 
macrophage ratio of approximately 1:14 can provoke OPN release, Treg cells were 
Fig.  35: Evaluation of T cell purity post-sorting and activation 
state after 4 days of incubation in presence of IL-2 and an isotype 
control antibody (Ig) or CD28-SA. Conventional CD4+ T cells were 
defined as CD25-Foxp3-, regulatory T cells as CD25+Foxp3+. Activation 
was assessesd by an expression analysis of the proliferation marker 
Ki67. (Weirather et al., Circulation Research, 2014168)   
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successively titrated from the co-culture system. Even at a Treg cell : monocyte ratio 
of 1 : 25,  OPN concentrations in culture supernatants were still higher as compared 
to monocytes cultivated alone (Fig.  36B).     
 
 
 
To investigate whether Treg cells induce OPN secretion from monocytic cells by Treg 
cell-derived soluble mediators and, moreover, to test weather monocytes/ 
macrophages are indeed responsible for the high OPN concentrations in 
supernatants of co-culture experiments, Treg cells were activated by CD28-SA and IL-
2 in vitro. After 4 days of incubation, the supernatant was mixed with culture medium 
containing freshly purified monocytes/ macrophages at a volume ratio of 1:1. 
Monocytic cells cultivated in the supernatant of Treg cells that had been cultured in 
presence of an isotype control antibody and IL-2 were used as reference control. 
After 3 days of incubation, monocytic cells had released high amounts of OPN in 
response to mediators in the supernatant of CD28-SA-activated Treg cells, but not in 
presence of supernatant from non-activated Treg cells (Fig.  37A). OPN release from 
monocytic cells correlated with CD206 and arginase I mRNA upregulation (Fig.  
37B). 
 
Fig.  36: Osteopontin (OPN) concentrations in cell culture 
supernatants. A: Monocytic cells (MΦ), regulatory (Treg) and conventional 
(Tconv) CD4+ T cells were cultivated for 4 days alone or in the indicated 
combinations in presence of CD28-SA or an isotype control antibody (Ig). 
All cultures were supplemented with IL-2. OPN concentrations were 
assessed by ELISA (n=3-4 per group). B: OPN concentrations in the 
supernatant of Treg cell/ monocyte (MΦ) co-cultures cultivated at different 
ratios. (Weirather et al., Circulation Research, 2014168) 
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Having observed that Treg cell-derived soluble mediators influence monocyte/ 
macrophage differentiation in vitro, Treg cell supernatants were analyzed for cytokine 
composition. In comparison to Treg cells cultivated in presence of an isotype control 
antibody and IL-2, simultaneous presence of CD28-SA and IL-2 led to a significantly 
increased secretion of IL-10, IL-13 and TGFβ1, but not IL-2 or IL-4 (Fig.  38). The 
capacity of IL-10, IL-13 and TGFβ1 to induce OPN release from monocytic cells was 
further investigated. Supplementation of culture medium with TGFβ1 alone did not 
reinforce OPN release from monocytic cells in vitro (Fig.  38). However, the 
simultaneous presence of TGFβ1 and IL-10 provoked a strong OPN release from 
monocytic cells that could be further increased by addition of IL-13. However, 
neutralization of TGFβ1 dramatically restrained IL-10- and IL-13-driven OPN 
secretion.  
 
 
Fig.  37: Treg cell-derived soluble mediators induce osteopontin (OPN) release and 
expression of M2 marker genes in monocytic cells (MΦ) in vitro.  A: OPN release from 
monocytic cells cultivated for 3 days in culture medium alone supplemented with supernatant 
from unstimulated Treg cells, or culture medium supplemented with supernatant derived from 
CD28-SA-activated Treg cell cultures. B: Real-time RT-PCR analysis of M2-associated CD206 
and arginase I in monocytic cells (MΦ) cultivated alone or in presence of Treg cell supernatant. 
(Weirather et al., Circulation Research, 2014168) 
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Conclusively, CD28-SA-stimulated Treg cells released high amounts of IL-10, IL-13 
and TGFβ that synergistically drove OPN release and M2 macrophage polarization in 
vitro.  
5.12  Therapeutic Treg cell activation by IL-2/ anti-IL-2 monoclonal   
antibody complexes provokes M2-like macrophage differentiation 
and accelerates scar tissue formation 
 
Therapeutic Treg cell activation after MI by CD28-SA administration improved survival 
by reducing the incidence of left-ventricular ruptures. CD28-SA infusion represents 
therefore a promising modality to treat patients with MI. However, additional 
strategies to activate Treg cells in vivo have been developed, e.g. by administrating 
recombinant human IL-2 at low dosage171. IL-2 in complex with a particular anti-IL-2 
monoclonal antibody (IL-2 mAB), hitherto used only experimentally, holds even more 
clinical potential compared to IL-2 alone by enhancing Treg cell functions on a per cell 
basis164. IL-2/ IL-2 mAB complexes were therefore administered to infarcted mice. 
Treg cell expansion kinetics after IL-2/ IL-2 mAB injection are different from the 
proliferative behaviour after CD28-SA treatment164, 170, 172. A pilot study was therefore 
conducted to determine an eligible time point to start the IL-2/ IL-2 mAB treatment of 
infarcted mice. Principal criteria for an optimal regimen were a supportive induction of 
Fig.  38: Treg cell-derived IL-10, IL-13 and TGFβ1 induce osteopontin secretion from 
monocytic cells in vitro.  A: Cytokine concentrations in supernatants from Treg cells 
cultivated for 4 days in presence of CD28-SA or an isotype control antibody (Ig) (n=2 per 
group). B: Osteopontin (OPN) concentrations in the supernatant of monocytic cells 
cultivated in presence of the indicated cytokines or a neutralizing anti-TGFβ antibody (n=4 
per group, *P<0.05 vs. MΦ+TGFβ1+IL-10). (Weirather et al., Circulation Research, 2014168) 
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M2 cells and augmented scarring in the reparative phase that did not interfere with 
the early inflammatory stage of postinfarction healing. IL-2/ IL-2 mAB administration 
on three consecutive days beginning on day 1 post-MI turned out to represent an 
adequate regimen that fulfilled the requirements. Compared to animals treated with 
vehicle solution, IL-2/ IL-2 mAB injection caused increased frequencies of Foxp3-
positive cells among CD4+ T cells in mediastinal lymph nodes and the infarct zone on 
day 5 after MI (Fig.  39A). Bulk scar tissue homogenates of IL-2/ IL-2 mAB-treated 
mice showed a tendency towards an increased expression of M2-inducing IL-10 (Fig.  
39B). Similar to CD28-SA-treated mice, IL-13 was significantly upregulated after IL-2/ 
IL-2 mAB injection as compared to controls, but, however, not TGFβ1 (Fig.  39B). In 
accordance with upregulated M2-inducing factors, M2-associated arginase I as well 
as CD206 expression were significantly heightened in hearts of IL-2/ IL-2 mAB-
treated mice (Fig.  39C). M2 macrophage differentiation correlated with elevated 
expression of pro-collagen alpha 1 (III) (Fig.  39D). However, regarding pro-collagen 
alpha 1 (I) mRNA synthesis, no significant differences were found between the 
treatment groups (Fig.  39D). In summary, the observation of reinforced M2-like 
macrophage polarization and augmented scar tissue construction after therapeutic 
Treg cell activation could be confirmed in an independent approach of Treg cell 
expansion, i.e. by a therapeutic IL-2/ IL-2 mAB administration. 
Conclusively, the results of the present study indicate that therapeutic Treg cell 
activation after MI generally represents a suitable strategy to improve cardiac infarct 
healing.  
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Fig.  39: Therapeutic Treg cell expansion by IL-2/ IL-2 mAB complexes elicits M2-like 
macrophage polarization and accelerated scar tissue construction evaluated 5 days 
post-MI. A: Frequency of Foxp3-positive cells among CD4+ T cells in heart-draining lymph 
nodes and scar tissue of treated mice. B: Real-time RT-PCR analysis of the M2-inducing 
cytokines interleukin (IL)-10, IL-13 and TGFβ1 (n=2-3 per group, *P<0.05). C: mRNA 
expression of M2-associated arginase I and CD206 (n=2-3 per group, *P<0.05). D: mRNA 
synthesis of scar-forming collagen alpha 1 (III) (Col3a1) and collagen alpha 1 (I) (Col1a1) 
(n=2-3 per group, *P<0.05). 
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6 Discussion 
 
The role of innate immunity in postinfarction cardiac wound healing and remodeling 
has been studied in great detail. In contrast, the relevance of adaptive immunity in 
this context has been widely disregarded. The present study focused on the 
activation of CD4+ T cells after MI and systematically addressed their role in cardiac 
wound healing and remodeling.  
6.1 Antigen-dependant CD4+ T cell activation post-MI 
In terms of adaptive immune reactions, T cell priming by APCs occurs not directly at 
the location of inflammation, but in lymph nodes that drain the inflammatory site. T 
cell activation after MI requires therefore passive antigen drainage to lymphoid-
resident APCs, or active antigen transport to the lymph nodes by migratory cells such 
as macrophages or dendritic cells that both reside within the heart during steady 
state conditions115, 173. Furthermore, a large proportion of macrophages arises from 
infarct-infiltrating monocytes after MI. A recent study demonstrated that monocyte-
derived as well as tissue-resident macrophages mediate cardiomyocyte efferocytosis 
after angiotensin II-induced cardiac inflammation173. Both cardiac macrophage 
subsets represent potent APCs with capacity to activate T cells in vitro suggesting 
that these myeloid cells might also play a role in T cell priming in the setting of MI173.  
The fundamental role of APCs in terms of MI is underscored in mice depleted 
from CD11c+ cells comprising dendritic cells and, most likely, also distinct 
macrophage subsets26, 174. The postinfarction phenotype of CD11c+ cell-ablated mice 
is characterized by an escalated cardiac inflammation along with M1-like 
macrophage polarization that correlates with deteriorated healing and heart 
function175. The observation that depletion of CD11c+ APCs aggravates clinical 
outcome is in line with the interpretation that self-peptide-MHC recognition is crucial 
for proper T cell activation after MI as OT-II mice in which most CD4+ T cells are 
“blind” for cardiac self-antigens exhibit a fatal postinfarction outcome.  
Physiological CD4+ T cell expansion kinetics were evaluated in heart-draining lymph 
nodes where both Foxp3- conventional and Foxp3+ regulatory T cells were activated 
after MI. In contrast to WT animals, heart-draining lymph nodes of OT-II mice did not 
show an expansion of CD4+ T cells indicating that self-antigen recognition constitutes 
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an indispensable prerequisite for CD4+ T cell activation after MI. However, the 
expansion of Treg cells over concomitantly proliferating conventional CD4+ T cells in 
infarcted wildtype mice closely resembles T cell expansion kinetics in primary 
immune reactions to foreign pathogen-derived antigens176, 177, implying a release of 
cardiac self-antigens that are immunologically privileged during steady state 
conditions. In accordance with this postulation, myocardial self-antigens capable of 
eliciting CD4+ T cell reactions have been described. Heart-specific α-myosin heavy 
chain (α-MHC), for instance, is not expressed in mTECs of human and mouse thymi 
resulting in a failure to delete α-MHC-reactive T cells from the repertoire178. As a 
consequence, immunization with α-MHC in Complete Freund´s Adjuvant provokes 
the development of severe autoimmune myocarditis in susceptible mouse strains179. 
In the context of sterile inflammation post-MI, however, the putative release of α-
MHC did not induce a detrimental activation of auto-reactive CD4+ T cells in this 
setting. The MHC haplotype might play a central role for the observation that adverse 
autoimmunity did not develop in the utilized C57BL/6 mice. Laboratory mouse strains 
are intentionally homozygous and encode a unique set of MHC alleles termed the 
MHC haplotype6. As each mouse strain encodes a unique set of MHC molecules, the 
diverse strains exhibit a different capacity to present distinct antigens to T cells6, 180. 
All experiments in this study were conducted in mice possessing a C57BL/6 
background that bear the H-2b MHC haplotype. Interestingly, this mouse strain is not 
susceptible to autoimmune myocarditis after α-MHC immunization in contrast to 
animals of BALB/c background encoding H-2d. The MHC haplotype and 
consequently the capacity to present distinct peptides may therefore be decisive for 
the quality of CD4+ T cell reactions in terms of MI and lead to “protective auto-
immunity” as observed in infarcted C57BL/6 mice, or, by any chance, result in 
detrimental autoimmunity as observed in α-MHC-immunized BALB/c animals. 
However, so far, the influence of genetic MHC predisposition on the outcome after MI 
has not been systematically addressed.    
Thymus-derived Treg cells and conventional T cells show little overlap with respect to 
their antigen specificity. In terms of thymic development, autoreactive conventional T 
cells undergo deletion from the repertoire whereas Treg cells become rather selected 
by self-antigen recognition. In the light of the fact that cardiac-specific α-MHC is 
absent in mTECs and cTECs, Treg cells specific for α-MHC-derived peptides may not 
arise during thymopoiesis, implying that α-MHC may not be involved in the priming of 
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Treg cells post-MI. However, a plethora of potential cardiac self-antigens becomes 
likely released during ischemic injury. Troponin, for instance, has been reported to 
provoke the proliferation of CD4+ T cells in vitro157. Furthermore, nasal vaccination 
with this protein has been reported to improve heart function after myocardial 
ischemia-reperfusion injury157 suggesting troponin as a candidate antigen that might 
be involved in the physiological activation of CD4+ T cells after MI.  
6.2 CD4+ T cells facilitate healing post-MI 
In order to test the functional relevance of CD4+ T cells in wound healing, MI was 
induced in two different CD4+ T cell-deficient mouse strains, i.e. MHC II KO mice 
lacking MHC class II-restricted CD4+ T cells, and OT-II mice harboring CD4+ T cells 
with restricted (self-) antigen reactivity. Both mouse strains showed a significantly 
higher mortality during the first week after MI due to a prevalence of left-ventricular 
ruptures indicating pronounced healing deficits. Both mouse strains were 
characterized by an attenuated and disarrayed scar tissue construction implying 
either an impaired myofibroblast function, or a deregulated activation of collagenolytic 
enzymes in the infarct zone of these mice. The pronounced phenotype of OT-II and 
MHCII KO mice, however, is most likely the result of both a lack of anti-inflammatory 
Treg cells in combination with an absence of conventional CD4+ T cells that most 
likely also directly contribute to the facilitation of postinfarction healing. An array of T 
cell-derived mediators is capable of fine-tuning the reparative response. IL-13, for 
instance, has been demonstrated to directly modulate myo-fibroblast function fuelling 
cell proliferation and collagen deposition181, 182. The impaired scar tissue formation in 
CD4+ T cell-deficient mice may further represent a consequence of pronounced 
collagen degradation in these hearts. Dysregulation of collagenolytic MMP-9 
constitutes a critical determinant for the development of left-ventricular ruptures183, 
184
. A lack of T cell-derived IL-10 may have aggravated clinical outcome in OT-II and 
MHCII KO mice as IL-10 signaling in the infarct zone has been reported to reduce 
both MMP-9 expression and activity185, 186. Most importantly, macrophage 
polarization is pivotally influenced by various T cell mediators. It is likely that CD4+ T 
cell-deficient mice exhibit a disturbed macrophage compartment post-MI that causes 
impaired scarring and, ultimately, the emergence of left-ventricular ruptures.  
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6.3 Treg cell depletion deteriorates postinfarction healing due to an 
impaired macrophage M2 polarization 
Healing after MI is characterized by an early pro-inflammatory Ly-6Chigh monocyte-
prevalent phase followed by an M2-like macrophage-dominant reparative stage. As 
Foxp3+ regulatory CD4+ T cells have well-known anti-inflammatory characteristics, 
this T cell subset was implicated to modulate postinfarction healing. To address 
whether the absence of Treg cells was responsible for the severe phenotype of MHCII 
KO and OT-II mice lacking the entire functional CD4+ T cell compartment, Treg cells 
were specifically depleted using two different approaches. Treg cell ablation in 
DEREG mice led to increased infarct sizes, left-ventricular dilatation and deteriorated 
cardiac function. The adverse phenotype of Treg cell-ablated DEREG mice was 
reconfirmed in a model of anti-CD25 antibody-mediated Treg cell depletion. Anti-CD25 
antibody treatment resulted in aggravated left-ventricular dilatation and, most 
importantly, to impaired survival rates suggesting that these animals deceased 
predominantly due to heart failure. The clinical outcome of exacerbated remodeling in 
Treg cell-depleted mice resembles the postinfarction phenotype of global CCR5 
knock-out mice that are characterized by an attenuated Treg cell influx into the infarct 
zone181. However, as other immune cells such as monocytes also employ CCR5 to 
infiltrate the healing myocardium, the study could not unambiguously indicate a 
causal relationship between Treg cell recruitment and outcome. 
Neither of the two Treg cell depletion models exhibited a prevalence of left-ventricular 
ruptures in contrast to MHCII KO and OT-II mice that showed a more severe 
phenotype characterized by a predisposition to develop ruptures. The attenuated 
outcome in Treg cell-deficient mice as compared to animals that feature a complete 
functional lack of CD4+ T cells points to a protective role of conventional CD4+ T cells 
in postinfarction healing. Both non-regulatory CD4+ and CD8+ T cells express 
significant amounts of the ecto-5′-nucleotidase CD73 that catalyzes a critical step in 
the synthesis of adenosine187. In fact, non-regulatory CD4+ and CD8+ T cells together 
account for approximately 50% of the synthesized adenosine in the infarcted heart 7 
days after MI187, 188. Adenosine signaling has emerged as a critical pathway that 
mitigates infarct inflammation and, moreover, that fosters scar tissue maturation in 
the infarct core188. Treg cell ablation led to an increased expansion of both CD4+ and 
CD8+ non-Treg cells that numerously accumulated in the infarcted myocardium. A 
presumably escalated adenosine synthesis in the infarct zone of Treg cell-deficient 
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mice may therefore have partially compensated the adverse effects of a maladaptive 
activation of conventional T cells in these mice characterized by a high synthesis rate 
of TNFα and IFNγ. 
The observation that Treg cell deficiency does not provoke left-ventricular ruptures is, 
prima facie, at odds with the finding that therapeutic Treg cell activation in CD28-SA-
treated mice reduces the occurrence of left-ventricular ruptures. However, 
therapeutic Treg cell activation provoked an escalated synthesis of scar-forming 
collagens and both TIMP-1 and TIMP-2 in the infarct region indicating that Treg and 
M2 cells accelerated or even augmented scar tissue construction that likely 
prevented ruptures. Treg cell depletion, in contrast, did not influence the expression of 
collagens or collagenolytic enzymes implicating that M1 cells or Treg cell deficiency do 
not restrain myofibroblast function during scarring.  
The phenotypes of both Treg cell depletion models were not entirely congruent 
with respect to the severity of postinfarction clinical outcome. The significantly 
impaired survival rate in anti-CD25 antibody-treated mice represents the most 
striking discrepancy in comparison to DTX-treated DEREG animals. As a limitation of 
this study, however, one cannot definitely rule out that anti-CD25 or DTX treatments 
have differentially influenced healing, or the occurrence of fatal cardiac arrhythmias 
as both treatments are known to be associated with potential off-target or indirect 
effects to some degree189, 190. DTX administration at the used dose, for instance, has 
been demonstrated to elicit neutrophilia and monocytosis in mice as early as two 
days after injection191. As both fractions of myeloid cells influence postinfarction 
healing, differences in the clinical phenotype between the two depletion models may 
result from an altered mobilization of monocytes and neutrophils. Furthermore, the 
anti-CD25 monoclonal antibody may have exerted off-target effects on other CD25-
bearing cells besides Treg cells such as activated conventional T cells, dendritic cells, 
or distinct NK cell subsets that may have also been depleted190. 
Infarcted hearts of both depletion models harbored elevated numbers of pro-
inflammatory myeloid cells, i.e. Ly-6Chigh monocytes, M1 cells and neutrophils. The 
reinforced influx of myeloid cells into the infarcted heart is in accordance to other 
models of healing and inflammation. In a rodent model for wound healing after burn 
injury, Treg cell depletion intensified the infiltration of innate immune cells into the 
lesion192. Furthermore, Treg cells can modulate chemokine synthesis at the site of 
inflammation to regulate the influx of myeloid cells193. The enhanced leukocyte 
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recruitment into hearts of Treg cell-deficient DEREG mice came along with a 
pronounced accumulation of conventional CD4+ as well as CD8+ T cells contributing 
to an increased expression of IFNγ and TNFα that are both individually capable of 
driving M1 differentiation.  
In comparison to wildtype littermates, Treg cell ablations prior to MI led to larger 
infarcts in DEREG mice in line with an exacerbated cardiac remodeling and function 
in both Treg cell depletion models. Mechanistically, heightened TNFα levels in 
combination with an M1 macrophage polarization state are likely responsible for the 
observed maladaptive phenotype. The deleterious impact of TNFα on postinfarction 
healing and remodeling is underlined in global TNFα knock-out mice that show a 
preservation of cardiac output post-MI194 as TNFα abates cardiac contractile function 
and has been shown to provoke cardiomyocyte apoptosis as well as left-ventricular 
dilatation195, 196. Aside of TNFα, iNOS-mediated effects are critically involved in 
cardiac deterioration post-MI. Several independent reports clearly indicate that 
pharmacological iNOS inhibition or genetic iNOS ablation correlates with a reduction 
of both infarct size and left-ventricular dilatation197, 198, 199, 200. The detrimental effects 
of iNOS on postinfarction healing and remodeling are ascribed to the NO-dependant 
cytotoxicity as NO-derived radicals along with an inactivation of sulphur-iron-centered 
enzymes lead to the disruption of essential metabolic pathways201, 202. M1-like 
macrophages in the healing myocardium of Treg cell-deficient DEREG mice showed a 
significantly increased iNOS expression that likely aggravated remodeling and infarct 
expansion due to a secondary loss of surviving cardiomyocytes. However, although 
the mRNA expression of collagenolytic MMP-2 and MMP-9 as well as their 
respective tissue inhibitors were not different in DEREG mice as compared to 
controls, an elevated overall collagenase activity cannot be definitely ruled out in 
these hearts. Secondary collagenase activation by reactive oxygen or nitrogen 
species at the protein level, for instance, may have further contributed to the 
exacerbated infarct expansion in DEREG mice203. In accordance with an elevated 
iNOS synthesis, monocytic cells in infarcts of Treg cell-deficient mice showed a 
diminished M2-like macrophage differentiation which has been demonstrated by 
unrelated reports to correlate with aggravated cardiac remodeling and function204, 205. 
The attenuated synthesis of scar-stabilizing OPN and FXIII presumably contributed to 
the cardiac deterioration in Treg cell-deficient mice206, 207, 208. The healing infarct of 
global OPN KO mice shows both disarrayed collagen deposition and reduced 
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collagen content indicating a fundamental role of OPN in postinfarction ECM 
assembly206, 209. Similarly, transglutaminase FXIII is involved in scar tissue 
construction post-MI as the enzyme promotes cross-linking of ECM components207, 
210
. Thus, deficits in ECM construction may have contributed to the impairment of 
cardiac performance in Treg cell-deficient mice. TGFβ synthesis in the infarcted 
myocardium is considered to represent a molecular switch suppressing the early 
postinfarction inflammation while activating reparative pathways208, 211. Lack of 
TGFβ1 synthesis by Treg cells in the infarct core of Treg cell-deficient mice, thus, 
presumably further corrupted healing (Fig.  40).  
  
 
 
 
 
 
 
 
6.4 Therapeutic Treg cell activation improves postinfarction wound 
healing by enhancing an M2-like macrophage polarization 
The observation that Treg cells facilitate healing after MI suggested that a therapeutic 
Treg cell activation could further improve the obviously beneficial influence of these 
cells on postinfarction outcome. The physiological Treg cell activation after MI was 
amplified by a single CD28-SA injection 2 days after surgery and led to a significantly 
Fig.  40: Proposed model depicting the mechanism for impaired healing in 
Treg cell-depleted mice. Treg cell depletion provokes an adverse activation and 
polarization of both CD4+ and CD8+ non-regulatory T cells in heart-draining lymph 
nodes of infarcted mice. These non-Treg cells accumulate in the infarcted 
myocardium and polarize resident macrophages towards an M1-like state by 
releasing IFNγ and TNFα. The M1 polarization state is characterized by an 
increased expression of deleterious iNOS in line with a reduced synthesis of 
healing-promoting osteopontin (OPN), transglutaminase (FXIII) and transforming 
growth factor beta 1 (TGFβ1).     
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improved survival. Echocardiography revealed no significant differences between 
CD28-SA-treated mice and the respective control group. However, the improved 
survival of mice with large MI after CD28-SA injection likely explains the fact that no 
mitigation of adverse left-ventricular dilatation was found in this group as compared 
to controls.  
CD28-SA treatment reinforced the accumulation of Treg cells in the infarct zone 5 
days after MI in contrast to conventional CD4+ T cells that did not show an increased 
influx. The observed T cell mobilization kinetics in treated mice are in line with former 
reports.  Early after CD28-SA-mediated activation, T cells are effectively retained in 
secondary lymphoid organs212. Foxp3+ Treg cells, however, experience a second 
phase of increased motility post-stimulation facilitating Treg cell homing212. The 
increased Treg cell accumulation in the hearts of CD28-SA-treated mice strengthens 
the hypothesis that improved healing is attributable to infarct-infiltrating Treg cells that 
exert their beneficial function directly in the healing myocardium.  
M2 macrophages have potent anti-inflammatory characteristics and represent an 
integral pillar in wound healing processes as M2 cells crucially modulate scar tissue 
formation139, 142, 143. Consistently, experimental modulation of macrophage 
polarization towards an M2-like differentiation state has been demonstrated to 
improve wound healing post-MI213, 214. Alternatively activated or M2-like macrophages 
differentiate in presence of IL-4, IL-13, IL-10 or TGFβ139, 144. Treg cells secreted little 
TGFβ1 but considerable amounts of IL-10 and IL-13 upon CD28-SA stimulation in 
vitro which capacitated the cells to induce an M2 polarization state even at the 
unpropitious Treg cell : monocyte/ macrophage ratio of 1:25 in co-culture experiments. 
CD28-SA treatment provoked an upregulation of TGFβ1, IL-10 and IL-13 in scar 
tissue homogenates implying that Treg cells presumably drove the observed M2-like 
macrophage differentiation in these hearts. M2 cells, in turn, might have further 
contributed to the M2-creating milieu by secretion of IL-10 and TGFβ forming a 
positive feedback loop. In addition to cytokine release, Treg cells might also modulate 
macrophage polarization in a contact-dependant manner. However, given the relative 
low Treg cell : macrophage ratio of approximately 1:14, a contact-mediated 
mechanism is likely insufficient to polarize a large proportion of myeloid cells towards 
M2 cells.  
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6.5 Molecular mediators improving wound healing after therapeutic Treg 
cell activation 
CD28-SA treatment led to an increased amount of collagen in the infarct zone before 
completion of healing indicating augmented or accelerated scar tissue construction in 
these mice. TGFβ signaling is a prominent driver of collagen deposition by (myo-) 
fibroblasts142, 215 and both Treg and M2 cells likely contributed to the escalated TGFβ1 
levels detected in the infarct zone of CD28-SA-treated mice. Moreover, the increased 
abundance of IL-13 in these hearts presumably further instigated collagen synthesis 
in a synergistic fashion216, 217.   
The matricellular protein OPN is a key player in wound healing and scar tissue 
formation after MI209. Thus, the observed increase in OPN expression in the infarct 
zone of CD28-SA-treated mice likely improved the formation of a stable scar. 
As OPN favors construction of a mechanically robust scar, an in vitro test system 
was set up to evaluate the contribution of monocytes/ macrophages and Treg cells to 
the amount of OPN in the healing infarct in vivo. CD28-SA-stimulated Treg cells 
secreted TGFβ1, IL-10 and IL-13 that synergistically elicited OPN release from 
monocytic cells in line with an M2-like macrophage polarization. Neutralization of 
TGFβ reduced OPN secretion which is in accordance with the observation that M2 
differentiation requires TGFβ signaling218. However, TGFβ receptor engagement 
alone was not sufficient to provoke OPN release from monocytic cells implying that 
TGFβ is necessary to render the cells responsive to IL-10 and IL-13.  
Monocytes and macrophages represent the most abundant leukocyte fraction in the 
reparative phase of postinfarction healing. Therefore, it is likely that the major 
proportion of OPN in the healing myocardium is derived from monocytic cells. 
However, other cell types such as myofibroblasts may have additionally contributed 
to the elevated OPN synthesis219.    
Aside from OPN, transglutaminase FXIII crucially stabilizes scar tissue integrity by 
cross-linking ECM components210. Global FXIII deficiency in mice and impaired 
expression in men correlates with a higher incidence of left-ventricular ruptures post-
MI207, 220. Consistently, exogenous administration of recombinant FXIII to infarcted 
mice results in increased collagen density in line with a reduction of rupture 
frequencies220. The increased expression of FXIII in the healing myocardium of 
CD28-SA-treated mice, thus, presumably further improved the scarring process (Fig.  
41). 
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Fig.  41: Model for improved healing after therapeutic CD28-SA administration. During early 
infarct healing, infiltrating Ly-6Chigh monocytes and M1 macrophages mediate cardiac inflammation. As 
healing proceeds, M2-like macrophages emerge in the scar characterized by an inflammation-
resolving and healing-promoting transcriptional profile. Therapeutic CD28-SA administration provokes 
the accumulation of activated Treg cells in the healing myocardium. Treg cell-derived interleukin (IL)-10, 
IL-13 and transforming growth factor beta (TGFβ1) synergistically boost M2-like macrophage 
polarization resulting in increased synthesis of transglutaminase factor XIII (FXIII), osteopontin (OPN) 
and transforming growth factor beta 1 (TGFβ1). OPN, TGFβ and Treg cell-derived IL-13 promote 
collagen deposition by myofibroblasts. FXIII mediates cross-linking of extracellular collagen matrix 
(ECM) components bracing scar tissue integrity.     
6.6 Implications for the treatment of patients with MI 
The concept that a deregulated inflammatory reaction exacerbates postinfarction 
healing is widely accepted and various experimental studies underline that 
inflammation resolution in the right temporal context is of paramount importance. As 
Treg cells have well-known anti-inflammatory characteristics, efforts have been taken 
to harness these cells for the treatment of inflammatory disorders. The present study 
demonstrated that Treg cells beneficially influence postinfarction wound healing by 
alleviating inflammation in the healing myocardium. Therapeutic Treg cell activation 
especially improved the replacement of the irreversibly injured myocardium by a 
collagenous scar preventing left-ventricular ruptures. Although the incidence of 
ruptures is relatively low in men as compared to C57BL/6 mice, it seems plausible 
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that an accelerated healing or improved scarring may attenuate both infarct 
expansion and adverse left-ventricular dilatation in human patients.   
Pro-fibrotic actions in the non-injured remote myocardium represent potential 
negative effects after CD28-SA treatment that may compromise cardiac function. 
However, activated Treg cells in CD28-SA-treated mice modulate pro-fibrotic 
pathways in macrophages and fibroblasts that both accumulate predominantly 
spatially restricted in the healing infarct core early post-MI. Furthermore, CD28-SA-
activated Treg cells did not infiltrate non-injured cardiac parenchyma as sham-
operated mice exhibited no accumulation of Treg cells after CD28-SA injection, 
implying that macrophages and fibroblasts in the remote myocardium of infarcted 
mice may not have been stimulated to promote fibrosis. The long-term survival of 
CD28-SA-treated animals further indicates that negative effects were, if at all 
present, far from annihilating the beneficial effects of CD28-SA administration on 
postinfarction healing.  
In March 2006, a first in-man trial to activate Treg cells utilizing the human CD28-SA 
TGN1412/ TAB08 yielded a catastrophic result as volunteers experienced a lift-
threatening cytokine release syndrome221, 222. However, more recently, the same 
human CD28-SA has been successfully tested in a phase I clinical trial by 
administration of significantly lower antibody amounts resulting in increased plasma 
levels of the Treg cell signature mediator IL-10222. Thus, the usage of CD28-SA to 
activate Treg cells still holds potential for the treatment of human patients. However, 
alternative strategies to activate Treg cells in vivo have been successfully pursued. 
Recombinant human IL-2 administered at low dose, for instance, has been 
successfully used to expand Treg cells over conventional T cells in men171. IL-2/ IL-2 
mAB complexes, hitherto used only in experimental settings, bear even more clinical 
potential as complexed IL-2 further increases suppressive Treg cell functions on a per 
cell basis as compared to low dose IL-2 treatment164. Using an experimental mouse 
model of myocardial infarction, the present study demonstrated that an administration 
of IL-2/ IL-2 mAB complexes, indeed, was capable of inducing a beneficial M2-like 
macrophage polarization. Although the expression of M2-inducing cytokines after IL-
2/ IL-2 mAB administration was not as pronounced as in hearts of CD28-SA-treated 
mice, macrophages and myofibroblasts functions were still sufficiently reinforced to 
promote healing as collagen alpha 1 (III) and, by trend, collagen alpha 1 (I) synthesis 
was upregulated in the emerging scar.   
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The results of this study are especially of high clinical relevance since a modulation 
of Treg cells and, subsequently, the monocyte/ macrophage compartment was 
conducted in a therapeutic fashion. As healing is considerably slower in men as 
compared to rodents, there might be a therapeutic window of days to weeks in 
humans to prevent or attenuate detrimental infarct expansion, left-ventricular 
remodeling, or even infarct rupture. 
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8 Appendix  
8.1 Abbrevations 
A   ampere 
ADP    adenosine diphosphate 
α-SMA  alpha smooth muscle actin 
APC   antigen presenting cell 
APS    ammonium peroxodisulphat 
ATP    adenosine trisphosphate 
BSA    bovine serum albumin 
°C    Degree Celsius 
Ca2+    calcium  
CD   cluster of differentiation 
DAMP  danger-associated molecular pattern 
ddH2O   double-desalted water 
DTR   diphtheria toxin receptor 
DTX   diphtheria toxin 
ECL    enhanced chemiluminescence 
ECM    extracellular matrix 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immuno absorbance assay 
et al.    et alteri 
FCS    fetal calf (bovine) serum 
Fig.    figure 
FACS   fluorescence-activated cell sorting 
FITC    fluorescein isothiocyanate 
Foxp3   Forkhead-Box-Protein P3 
FSC    foreward scatter 
FXIII   transglutaminase factor XIII 
g    gram 
h    hour(s) 
HCl    hydrogen chloride 
HRP    horseradish peroxidase 
H2O    water 
Ig    immunoglobulin 
IL    interleukin 
IFNγ   interferon gamma 
iNOS   induced NO synthase  
IU   international units 
kDa    kilo Dalton 
KO   knock-out 
Ly-6C   lymphocyte antigen 6C 
Ly-6G   lymphocyte antigen 6G 
M    molar 
MI   myocardial infarction 
MFI    mean fluorescence intensity 
mg   milligram 
min    minute(s) 
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ml    milliliter 
mLN   mediastinal lymph nodes 
µ    micro 
Mφ   macrophage 
NaCl    sodium chloride 
NaOH   sodium hydroxide 
OPN   osteopontin 
PAMP   pathogen-associated molecular pattern 
pg   picogramm 
PBS    phosphate buffered saline 
PerCP  Peridinin chlorophyl 
PCR    polymerase chain reaction 
PE    phycoerythrin 
PRR   pathogen recognition receptor 
rpm    rounds per minute 
RT    room temperature 
SE    standard error 
SDS    sodium dodecyl sulfate 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SSC    sideward scatter 
TGFβ   transforming growth factor beta 
TNFα    tumor necrosis factor-α 
Treg cell   regulatory T cell 
TRIS    trishydroxymethylaminomethane 
V   Volt 
vWF    von Willebrand factor 
wt    wildtype 
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